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ABSTRACT 
Ding Xu: Structural and Mutational Analysis of Heparan Sulfate Biosynthetic Enzymes 
(Under the direction of Jian Liu, Ph.D.) 
 
Heparan sulfate (HS), a universally expressed and abundant macromolecule found at 
the cell surface and in the extracellular matrix, plays fundamental roles in a wide variety of 
physiological and pathophysiological processes, and it represents a promising therapeutic 
agent for current and future pharmaceutical research.   The diverse functions of HS rely on its 
diverse structures, resulting from modifications by many HS biosynthetic enzymes.  
Understanding HS fine structure regulation by these enzymes is fundamental to therapeutic 
intervention targeting numerous HS involved diseases.  Towards this end, characterization of 
all HS modification enzymes and their structure-function relationships is essential.   In this 
research, the substrate specificity of 3OST6, a novel HS 3-O-sulfotransferase, was 
characterized using a CHO cell line stably expressing 3OST6.  The HS structure generated 
by 3OST6 was also determined to be capable of serving as an HSV-1 entry receptor.   Next, 
facilitated by a novel recombinant protein expression system developed in the lab, HS 
3OST5 was purified and its crystal structure was solved in complex with 3′-
phosphoadenosine 5′-phosphate; while HS 2OST was purified and is currently under 
crystallization trials.   Moreover, a systematic mutational study of HS 2OST and chondroitin 
sulfate (CS) 2OST, an enzyme homologous to HS 2OST modifying CS chain, was conducted 
based on homology models derived from structure-solved sulfotransferases.   From this study, 
                                                                        iii 
a co-factor binding site and a potential substrate binding site were identified.  More 
importantly, a unique catalytic site of HS 2OST was proposed, which is not present in CS 
2OST even though these two enzymes catalyze the same chemical reaction.  This study 
provided the first structure-function relationship data for these two enzymes.  Furthermore, it 
prompted us to identify the authentic enzyme possessing the function of HS 2OST in 
Drosophila, which was mistakenly assigned to another homologous protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                        iv 
 
 
To my wife, Danyin Song, whose love and support made this work possible,  
and to my father, Shangxin Xu, and mother, Bin Gao, who provided me an excellent 
education and respected all my decisions, 
and to my aunt, Shangzhe Xu, who offered enormous support of my education.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                        v 
 
 
 
 
 
ACKNOWLEDGMENTS 
 
I wish to express my sincerest gratefulness to my mentor, Jian Liu, for his exceptional 
guidance during my developement as a scientist.  Dr. Liu’s perseverance, frankness and 
optimism greatly influenced my view of scientific research in the past five years.  And above 
all, his great confidence in me not only makes me a better scientist, but a better person.   
I would like also to thank Dr. Lars Pedersen and Andrea Moon for their assistance with the 
structural and mutational studies of HS 3OST5 and HS 2OST, Dr. Robert Linhardt and Dr. 
Eva Munoz for their collaboration on the enzymatic synthesis of HS on sensor chips and 
3OST1 kinetics studies, Dr. Deepak Shukla and Dr Vaibhav Tiwari for their assistance with 
the virus entry assays in the 3OST6 work.  I extend my thankfulness to the members of my 
student advisory committee, Drs. Andrew Lee, Harold Kohn and Scott Singleton for their 
constructive advises on my research.  I also want to thank my lab mates, Dr. Suzanne 
Edavettal, Dr. Jinghua Chen, Dr. Michael Duncan, Dr. Ronald Copeland, Tanya Scarlett, 
Miao Chen, Heather Bethea, Courtney Jones and Renpeng Liu for their assistance.  
 
 
 
 
                                                                        vi 
                                       
 
TABLE OF CONTENTS 
                                
Page 
LIST OF TABLES................................................................................................................x 
LIST OF FIGURES.............................................................................................................xi 
ABBREVIATIONS...........................................................................................................xiii 
 
Chapter 
I. INTRODUCTION......................................................................................1
Structural Diversity and Structure Analysis of Heparan Sulfate..........................1    
Biosynthesis of Heparan Sulfate..........................................................................9  
         Building Block Synthesis............................................................................9 
         Chain Initiation..........................................................................................10 
         Chain Polymerization................................................................................13 
         Chain Modification....................................................................................15 
               N-Deacetylase/N-Sulfotransferase.......................................................15 
               Glucoronyl C5-Epimerase....................................................................20 
               Uronosyl 2-O-sulfotransferase............................................................22 
               Glucosaminyl 6-O-sulfotransferase.....................................................24 
                                                                        vii 
               Glycosaminyl 3-O-sulfotransferase.....................................................27 
Physiological Functions of Heparan Sulfate........................................................33 
                Anticoagulation..................................................................................33 
                Inflammation......................................................................................34 
                Angiogenesis......................................................................................36 
                Development.......................................................................................38 
                Neurogenesis......................................................................................40      
Pathophysiological Functions of Heparan Sulfate..............................................42                
                Viral Infectious Diseases....................................................................42 
                                     Tumor Progression..............................................................................45 
                  Statement of Problem..........................................................................................49 
  
II. MATERIALS AND METHODS.......................................................50 
                     Disaccharide Analysis of [35S]HS ......................................................................50 
                  Determination of the Binding of HS to antithrombin...................................50 
                     Determination of the Binding of HS to HSV-1 glycoprotein D.........................51 
            Stable Transformation of CHO Cells with 3-OST-6..........................................51 
            Western Blot Analysis of the Expression of 3-OST-6.......................................52 
            Metabolically Labeling 3-OST-6/CHO Cells and Preparation of [35S]HS........52 
                     Northern Blot Analysis of 3-OST-6...................................................................53 
            GroEL/ES Chaperonine Assisted E.coli Expression System ............................53 
                     Preparation of CHAP-Origami-B competent Cells...................................53 
                     Expression of Target Protein in CHAP-Origami-B Cells.........................54 
                                                                        viii 
            Protein Property Analysis by Gel Filtration Chromatography on HPLC...........54 
            Protein Purification by FPLC System................................................................55 
                      Ni Sepharose 6 Fast Flow Chromatography.............................................55 
                      MBP Affinity Chromatography................................................................56 
                      Hi-load Superdex 75/200 Gel Filtration Chromatography.......................56 
                     Remove (his)6 or Trx Tag by Protease Digestion...............................................57 
                     Preparation of Crystallization Sample................................................................59 
                     Site-directed Mutagenesis...................................................................................59 
                                Design of Mutagenesis Primers...............................................................59 
                                Small Scale Purification of the Mutants..................................................60 
            ITC Analysis of HS-2OST Mutants...................................................................61 
            PAP Chromatography Analysis of CS-2OST Mutant........................................61 
 
III. CHARACTERIZATION OF HS 3OST6.....................................63 
Substrate Specificity of 3-OST-6.......................................................................64 
3OST6 Modified HS Serving as HSV-1 Entry Receptor ..................................68 
Conclusion..........................................................................................................72 
 
IV. EXPRESSION AND CRYSTALLIZATION  
             OF HS 3OST5 AND HS 2OST.........................................................77 
Chaperonine Assisted Expression of 3-OST-5 in E. coli...................................78 
Increasing the Solubility of 3-OST-5 Through Targeted Mutations..................80 
                                                                        ix 
Chaperonine Assisted Expression of 2-OST in E. coli.......................................86 
Conclusion..........................................................................................................90 
 
V. MUTATIONAL ANALYSIS OF HS 2OST  
                AND CS 2OST...........................................................................................93 
         Substrate specificities of HS-2OST and CS-2OST.............................................95 
         PAPS Binding Residues of HS-2OST and CS-2OST.........................................96 
         Catalytic Residues of HS-2OST-and CS-2OST.................................................99 
                     Substrate Binding Residues of HS-2OST and CS-2OST.................................101 
                     Characterization of Drosophila HS-2OST.......................................................106 
                     Conclusion........................................................................................................109 
                 
VI. CONCLUTION........................................................................................116 
 
       APPENDIX1. Curriculum Vitae.................................................................121 
       REFERENCE........................................................................................................122 
 
 
 
 
 
 
 
                                                                        x 
LIST OF TABLES 
Table 
I.  The binding of 3OST6/CHO HS to gD and AT.............................................68
II. Tissue distributions of 3-O-sulfotransferase isoforms and the  
biological functions of 3-O-sulfated HS........................................................75
III. Summary of the analysis of the sulfotransferase activity of 3OST5  
solubility mutants...........................................................................................82
IV. Substrate specificities analysis of HS-2OST and CS-2OST..........................96
V. Analysis of HS-2OST and CS-2OST mutants defective in PAPS binding....97
VI. Analysis of HS-2OST and CS-2OST mutants defective in the  
catalytic function..........................................................................................101
VII. Analysis of HS-2OST and CS-2OST mutants potentially defective  
in substrate binding......................................................................................104
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                        xi 
LIST OF FIGURES 
 
Figure 
1. Structure of the disaccharide units of HS..........................................................2
2. Schematic view of the HSPG............................................................................2
3. Heparin lyase depolymerization of HS..............................................................5
4. Nitrous acid depolymerization of HS................................................................7
5. Schematic view of the HS backbone synthesis...............................................12
6. Schematic view of the HS modifications........................................................19
7. Structural features of 6OST.............................................................................27
8. Schematic view of the substrate specificities of 3OSTs..................................29
9. Stereo diagram of the HS binding site and catalytic site of 3OST3................31
10. The structure of AT-binding pentasaccharide.................................................34
11.  Schematic view of the interactions between HSV-1 viral particle  
and the cell surface binding receptor and entry receptors...............................44
12. The guideline of designing site directed mutagenesis primers........................60
13.  Multiple amino acid sequence alignment of human mouse 3OST6  
with mouse 3OST1, 3OST3A, 3OST5............................................................64
14. Western blotting analysis of 3OST6/CHO cell extract...................................65
15.  RPIP-HPLC chromatograms of the disaccharide analysis of HS  
isolated from 3OST6/CHO..............................................................................67
16. Entry of HSV-1 into 3OST6/CHO cells and CHO-K1 cells...........................69
17. Cell-cell fusion mediated by 3-O-sulphated HS..............................................71
18. Expression of 3OST6 mRNA in mouse tissues...............................................75
 
                                                                        xii 
19. RPIP-HPLC chromatograms of the disaccharide analysis of 
His3-OST-5 modified HS..................................................................................79
20. SDS-PAGE analysis of purified 3-OST-5.......................................................80
21. Alignment and structural property of the hydrophobic region of 3OST5.......83
22. SDS-PAGE analysis of the solubility of 3OST5 WT, I299E and F301R.......84
23. The superimposed structures of 3OST5, 3OST1 and 3OST3..........................85
24. SDS-PAGE analysis of the solubility of 2-OSTC’His and N’-His2-OST..............87
25. The effect of truncation length on the solubility of 2-OSTC’His.......................88
26. HPLC gel filtration analysis of the solubility of 2-OSTC’His...........................89
27. Structure of the disaccharide repeating units of HS and CS............................94
28. PAPS binding sites of HS-2OST and CS-2OST.............................................98
29. Stereo diagram of the catalytic site of HS-2OST..........................................100
30. The substrate binding regions of HS 3OST3, whose homologous 
regions were studied in HS-2OST and CS-2OST.........................................103
31. Multiple amino acid sequence alignment of the human HS-2OST  
 and the Drosophila Hs2st, Pip-PA and Pip-PF.............................................108
32. RPIP-HPLC chromatograms of the disaccharide analysis of  
dmHS-2OST modified and Chinese hamster HS-2OST  
modified CDSNS-heparin..............................................................................109
33. Overview of the predicted structure of HS/CS-2OST and the  
examined  residues.........................................................................................114
 
 
 
 
` 
 
                                                                        xiii 
ABBRIVIATIONS 
 
2OST    uronosyl 2-O-sulfotransferase 
3OST    glycosaminyl 3-O-sulfotransferase  
6OST    glycosaminyl 6-O-sulfotransferease 
AnMan   2,5-anhydromannitol 
AT    antithrombin 
C5-epi    glucoronyl C5-epimerase  
CDSNS   completely desulfated and N-sulfated 
CHAPOrigami-B  Origami-B cells containing GroEL/ES expression plasmid 
CS    chondroitin sulfate 
dmHS-2OST   Drosophila heparan sulfate 2-O-sulfotransferase 
ECM    extracellular matrix  
EST    estrogen sulfotransferase 
FGF(R)   fibroblast growth factor (receptor) 
GAG    glycosaminoglycan 
Gal    galactose 
GalNAc   N-acetylated galactosamine 
GalTI/II   HS galactosyltransferase I/II 
gB/C/D   HSV-1 glycoprotein B/C/D 
Glc    glucose 
GlcNS    N-sulfated glucosamine 
GlcNH2   N-unsubstituted glucosamine 
GlcNAc   N-acetylated glucosamine 
                                                                        xiv 
GlcNAcTI/II     HS GlcNAc transferase I/II 
GlcUA    glucuronic acid 
GlcUATI/II   HS glucuronosyltransferase I/II   
HIV    human immunodeficiency virus 
HS    heparan sulfate 
HSPG    heparan sulfate proteoglycan 
HSV    herpes simplex virus 
IdoUA    iduronic acid 
IdoUA2S   2-O-sulfated iduronic acid 
ITC    isothermal titration calorimetry 
NDST                                      N-deacetylase/N-sulfotransferase 
NiFF    Ni Sepharose 6 Fast Flow  
PAP    3′-phosphoadenosine 5′-phosphate 
PAPS    3′-phosphoadenosine 5′-phosphosulfate 
RPIP-HPLC   reverse-phase ion-pairing HPLC 
ST    sulfotransferase 
Trx    thioredoxin  
VEGF(R)   vascular endothelial growth factor (receptor) 
XT    xylosyltransferase 
Xyl    xylose 
∆UA     ∆4,5-unsaturated uronic acid 
 
 
      1
                          
  
 
                                 
Chapter I. Intoduction 
 
 
Structural Diversity and Structure Analysis of Heparan Sulfate  
Heparan sulfate (HS) belongs to a family of macromolecules known as 
glycosaminoglycans (GAGs), which also include chondroitin sulfate (CS), keratin sulfate and 
hyaluronic acid.  GAGs are unbranched polysaccharides consisting of repeating disaccharide 
units, which are distinct for different type of GAGs (1).  Heparan sulfate is comprised of 
uronic acid (glucuronic or iduronic acid) and glucosamine, linked to each other through β 1,4 
and α 1,4 glycosidic linkage (Fig. 1).  The disaccharide unit formed by glucuronic/iduronic 
acid and glucosamine repeat fifty to hundreds of times, forming the backbone of the heparan 
sulfate chain (2).  Multiple positions of the disaccharide unit are susceptible to modifications.  
For example, the uronic acid residue can be interconverted between glucoronic acid and 
iduronic acid by altering the configuration at the C5 position, and it can also be sulfated at 
the C2 position.  The C3 and C6 position of glucosamine residue can be sulfated, while the N 
position exists in the acetylated, sulfated or unsubstituted forms (Fig. 1) (1).  Because these 
modifications occur to the disaccharide repeats in different combinations, the HS is 
considered the most heterogeneous and structurally diverse biomolecule (2,3).  
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Figure 1. Struture of the disaccharide units of HS.  Positions susceptible for modification are labeled 
with the carbon number in blue.  
 
Figure 2. Schematic view of the HSPG.  The core proteins are shown in colored tubes, while the HS 
chains are shown in black lines.  The core protein of syndecan is a transmembrane protein, with 3-5 
HS attachment sites in the extracellular domain.  The core protein of glypican attaches to the 
membrane through a glycosyl-phosphatidylinositol (GPI) anchor, with 1-3 HS attachment sites.  The 
core protein of collagen is not directly attached to the cell membrane and three potential HS 
attachment sites.  
      3
Heparan sulfate is distributed on the cell surface and in the extracellular matrix (ECM) 
in the form of HS proteoglycans (HSPG).  In HSPG, HS chain attaches covalently to specific 
core proteins that serve as the HS carrier.  The HSPG core proteins can be divided into two 
groups based on their cellular locations.  Syndecans and glypicans are membrane-bound core 
proteins with HS chains attached onto their extracellular domains, and multiple isoforms of 
both usually exist in higher organisms.  Perlecan, agrin, and collagen XVIII are non 
membrane-bound core proteins that exist in the ECM, and they are all high molecular weight 
proteins with greater than 1500 amino acid residues (4). 
The major challenge facing the detailed structure-function relationship study of 
heparan sulfate is the unavailability of a fast and automated method to sequence HS.  This 
situation results from the nature of HS biosynthesis, which is not a template-driven process 
like that of DNA, RNA and protein.  This very nature of HS biosynthesis poses two obstacles 
for the structure analysis.  First, there is currently no way to amplify the structure of a 
specific HS chain, which precludes the molecular enrichment step necessary for sequence 
determination.  Second, the refined structure of HS is generated by a combination of chain 
modification enzymes, but none of the modifications proceeds to completion, giving rise to a 
highly heterogeneous population of HS, thus greatly complicating the sequence 
determination process.  These difficulties demand that the HS be purified prior to structural 
analysis, and current techniques only allow the HS oligosaccharides with fewer than 14 
residues to be successfully sequenced (1).   
The first step of HS structural analysis is usually depolymerization of the 
polysaccharide chain. This step breaks the HS into disaccharides, and the identity of the 
specific disaccharide unit can then be determined by various separation techniques such as 
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reverse phase ion-paring HPLC (RPIP-HPLC) or mass spectrometry.   
There are currently two commonly used depolymerization methods: the enzymatic 
method using heparin lyases or chemical method using nitrous acid.  The heparin lyases are 
isolated from the bacteria Flavobacterium heparium, and several isoforms are commercially 
available.  Different isoforms of heparin lyase have distinct substrate cleavage sites, thus 
these isoforms are generally used in combination when higher degrees of depolymerization is 
desired (5). It has been shown that heparin lyase I cleaves the glycosidic linkage between N-
sulfated glucosamine (GlcNS) and 2-O-sulfated iduronic acid (IdoUA2S), while heparin 
lyase III cleaves glycosidic linkage between N-acetylated glucosamine (GlcNAc) or GlcNS 
and nonsulfated glucuronic acid (GlcUA).  The substrate specificity of heparin lyase II 
appears to be promiscuous, it cleaves the linkage between GlcNAc/GlcNS and 
GlcUA/IdoUA.  A distinctive feature of the disaccharides resulting from heparin lyase 
disgestion is the generation of the ∆4,5-unsaturated uronic acid at the non-reducing end, 
which facilitates straightforward detection due to UV absorption at 232 nm .   It is important 
to note that a significant amount of HS remains in the oligosaccharide form even after an 
exhaustive digestion with a mixture of heparin lyases, which may result in underestimation of 
some disaccharide species (1).  
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Figure 3. Heparin lyase depolymerization of HS.  R represents a sulfate (SO3) or a proton (H); R’ 
represents a sulfate (SO3), a proton (H) or an acetate (Ac). Adapted from Jian Liu and Suzanne 
Thorp (1).  
 
            The most commonly used chemical method to degrade HS is by using nitrous acid.  
Nitrous acid breaks the glycosidic linkage at the reducing end of the glucosamine residue by 
reacting with either N-sulfated (GlcNS) or N-nonsulfated glucosamine (GlcNH2).  Because 
the GlcNAc does not react with nitrous acid, a deactylation step is usually taken by 
incubating HS with hydrazine, giving rise to the GlcNH2.  The nitrous acid reaction can then 
be carried out at two pH conditions.  At pH 1.5, nitrous acid predominantly reacts with 
GlcNS, whereas at pH 4.5-5.5, it primarily reacts with GlcNH2 (6,7).  A combination of 
nitrous acid treatment at low and high pH values will lead to an almost complete 
depolymerization of HS to disaccharide.  The advantage of HS structural analysis using 
nitrous acid degradation over the heparin lyase degradation is that it retains the configuration 
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of uronic acid, which allows discrimination between iduronic acid and glucuronic acid.  
However, the resulting disaccharide from nitrous acid degradation does not contain a UV 
chromophore, which requires the introduction of a radioactive tag or a fluorescent label (7,8).  
            RPIP-HPLC has been proven to be a very capable method for structural determination 
of disaccharide units generated from HS depolymerization.  By using slightly different 
chromatography conditions, a range of disaccharide structures with different sulfation states 
(non-sulfated to tetrasulfated) and distinct epimerization states (GlcUA or IdoUA) can be 
determined.  This method is a valuable approach in determining the substrate specificities of 
various HS modification enzymes (9-12), as well as confirming a characteristic disaccharide 
structure from natural sources (13).  The major limitation of this method is that it provides 
only fragment (disaccharide) information but nothing about how these fragments are 
connected.  In addition, it does not afford direct structural determination of oligosaccharide 
larger than a disaccharide.  
      7
              
  
Figure 4. Nitrous acid depolymerization of HS.  R represents a sulfate (SO3) or a proton (H). Adapted 
from Jian Liu and Suzanne Thorp (1). 
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           Recently, significant advances have taken place with the application of MS in HS 
structural analysis (14-17). MS affords the identification of overlapping oligosaccharides 
resulting from incomplete degradation through enzymatic or chemical methods, thus 
allowing deduction of the sequence of relatively large oligosaccharides and providing a more 
direct sequencing method.  Several MS techniques have been applied to oligosaccharide 
sequence analysis, including matrix-assisted laser desorption/ionization MS (MALDI-MS) 
and electrospray ionization MS (ESI-MS).  In a most recent study, by using a RPIP-
HPLC/ESI-MS method, a tetradecasaccharide derived from partial heparin lyase digestion of 
bovine lung heparin was successfully sequenced (14).  In this method, RPIP-HPLC was used 
to fractionate the oligosaccharide mixture resulting from heparinase depolymerization, 
largely based on fragment size.  Next, the size-defined oligosaccharides were subjected to 
ESI-MS analysis individually.  Only one major peak was observed for the di-, tetra- and 
hexasaccharide in the mass spectra.  The spectra for octa- through tetradecasaccharide tended 
to be a little more complex with various adduct forms, but nevertheless could be easily 
interpreted.  This study clearly demonstrated that the modified RPIP-HPLC/ESI-MS method 
has a great potential to sequence highly charged polymers like heparin.  However, the future 
challenges include: first, further optimization of the current method is necessary to simplify 
the mass spectra obtained from oligosaccarides larger than tetradecasaccaride; and second, 
more sophisticated fractionation methods are required for effective separation of 
oligosaccharides derived from HS depolymerization, which will be significantly more 
complex than the ones resulting from heparin depolymerization.    
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Biosynthesis of Heparan Sulfate  
The biosynthesis of heparan sulfate has been the kernel subject of the HS study field.   
A detailed view of HS biosynthesis would aid in elucidation of the structure-function 
relationship of HS in different biological contexts. In addition, a complete grasp of the 
biosynthesis mechanism would promote the development of the in vitro biosynthesis of HS 
or HS-like macromolecule for therapeutic purposes.  In the past decade, as a result of the 
sustained effort to understand the biosynthesis pathway of HS, all enzymes involved in HS 
biosynthesis have been cloned and purified, which greatly increased our knowledge of  this 
essential biological process.    
 
Building block synthesis   
HS biosynthesis takes place in the lumen of Golgi apparatus, where the component 
sugar residues are assembled and modified by synergistic actions of multiple Golgi 
membrane bound enzymes.  However, the majority of HS building blocks are not synthesized 
in the Golgi, but in the cytoplasma and are then transported into the Golgi lumen for HS 
biosynthesis.  The building blocks of HS include various activated sugar donors such as 
UDP-Xylose (UDP-Xyl), UDP-Galactose (UDP-Gal), UDP-N-acetylated-Glucosamine 
(UDP-GlcNAc) and UDP-Glucuronic acid (UDP-GlcUA); and the sulfate donor 3′-
phosphoadenosine 5′-phosphosulfate (PAPS) for the sulfation reaction. 
The UDP-Xyl, UDP-Gal and UDP-GlcUA are all derived from the activated 
glucose—UDP-glucose (UDP-Glc).  UDP-Gal is converted directly from UDP-Glc by 
epimerization at C4 position, while UDP-GlcUA is converted directly from UDP-Glc by 
UDP-Glc 6-dehydrogenase.  The UDP-Xyl is synthesized from UDP-GlcUA in the Golgi 
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apparatus by UDP-GlcUA decarboxylase (Fig. 5).  The biosynthesis of UDP-GlcNAc is more 
complex. It starts from fructose 6-phosphate, and requires three enzymes—a transaminase, an 
N-acetyltransferase and a mutase—to generate GlcNAc 1-phosphate, which is converted to 
UDP-GlcNAc by UDP-GlcNAc diphosphorylase.  Once synthesized, these UDP-sugars are 
transported into the Golgi lumen through specific nucleotide sugar transporters (Fig. 5) (18).  
The sulfation of the HS chain requires the universal sulfate donor PAPS.  PAPS is 
synthesized from ATP by a bifunctional enzyme—PAPS synthase—in animals.  The 
biosynthesis of PAPS occurs in both the nucleus and the cytoplasm, and PAPS is then 
transported into the Golgi by PAPS transportor for HS biosynthesis (19).  
 
Chain Initiation 
The biosynthesis of HS is initiated by formation of a tetrasaccharide linkage to the 
core proteins: GlcUAβ3Galβ3Galβ4Xylβ3-O-Ser, which also serves as the linkage for the 
biosynthesis of chondroitin sulfate (CS).  The formation of the tetrasaccharide linkage is 
catalyzed by the sequential actions of four glycosyltransferases, namely peptide O-
xylosyltransferase (XT), galactosyltransferase I (GalTI), galactosyltransferase II (GalTII) and 
glucuronosyltransferase I (GlcUATI) (Fig. 5) (3). 
XT is the first enzyme that triggers synthesis of the tetrasaccharide linkage at specific 
serine residues of the core proteins.  Two highly homologous XTs (XTI and XTII) have been 
identified in vertebrates, however, only XTI has been determined unambiguously to have XT 
activity (20,21).  The full length human XTI has recently been expressed in mammalian cells 
in active form and was shown to localize in the early Golgi cisternae (the part of Glogi that 
lies closest to the ER) (22).  Mechanisms of core protein attachment sites recognition by XT 
      11
have attracted a lot of interest,  given the pivotal role of XT in initiating synthesis of HSPG.  
A Ser-Gly dipeptide seems to be the minimum structural requirement for the xylosylation to 
happen, and a Glu or Asp residue is normally present in the vicinity of the Ser-Gly sequence 
(23,24).  Nevertheless, how XT recognizes the substrate core proteins and selectively modify 
specific Ser residues is still an open question.   
Once the xylose is installed onto the core protein, the glycan moiety is elongated by 
two galactosyltransferases, GalTI and GalTII.  GalTI belongs to the β1,4 GalT superfamily, 
transferring a galactose onto xylose to form Galβ4Xylβ3-O-Ser; while GalTII belongs to the 
β1,3 GalT superfamily, adding another galactose to form Galβ3Galβ4Xylβ3-O-Ser. Both 
GalTs were cloned and expressed, and their substrate specificities have been described. They 
have been shown to be located in the early-medial Golgi cinternae  (25-27). 
Synthesis of the tetrasaccharide linkage is finalized by GlcUATI, which is localized 
in the medial Golgi cinternae (27) and transfers GlcUA from UDP-GlcUA onto the existing 
glycan chain to form GlcUAβ3Galβ3Galβ4Xylβ3-O-Ser.  The crystal structure of GlcUATI 
has been solved with the UDP, Mn2+ and a substrate analogue Galβ3Galβ4Xyl, revealing that 
GlcUATI mainly recognizes the Galβ3Gal moiety, rather than the trisaccharide as a whole 
(28). More interestingly, a recent study demonstrated that sulfation at the Galβ3Gal moiety 
can greatly influence the enzymatic activity of GlcUATI, possibly providing a regulatory 
mechanism for PG biosynthesis (29).  In addition, sulfation of the galactose in the linkage 
region has only been seen in the CSPG and not in HSPG so far, suggesting it may serve as a 
signal to direct subsequent GAG synthesis (29,30).  Moreover, evidence suggests that the 
synthesis of the tetrasaccharide linkage can be carried out by GlcUAT-P, a promiscuous 
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glucuronosyltransferase that normally works on glycoproteins, providing a potential 
redundant mechanism for the linkage synthsis (31).   
       
Figure 5. Schematic view of HS backbone synthesis.  For simplicity, the synthesis of UDP-GlcNAc 
is not shown.  The EXT family member EXTL1 is also absent in the figure, which was shown to 
possess GlcNAcTII activity.     
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Chain polymerization 
 
The tetrasacchride linkage to the core protein provides a common precursor for 
biosynthesis of both HS and CS polysaccharide chains.  The decisive step that separates 
polymerization of HS from that of CS is the addition of a GlcNAcα4 at the non-reducing end 
of the tetrasacchride linkage.  This step should not to be confused with the polymerization 
reaction that also adds GlcNAcα4 residues (24).  For clarity, the enzyme that adds 
GlcNAcα4 to the linkage region is known as HS GlcNAc transferase I (GlcNAcTI), while 
the enzyme that adds GlcNAcα4 to the growing HS chain is known as HS GlcNAc 
transferase II (GlcNAcTII) (Fig. 5).  Two mammalian enzymes encoded by EXTL2 and 
EXTL3, belonging to the EXT (exostosin) gene family, have been suggested to possess the 
GlcNAcT-I activity (32,33).  Their activities have been demonstrated in vitro using synthetic 
tetrasacchride linkage analogue GlcUAβ3Galβ-O-naphthalenemethanol as the acceptor.  
However, the GlcNAcT-I activity could not be detected using the natural tetrasacchride 
linkage GlcUAβ3Galβ3Galβ4Xylβ3-O-Ser as the acceptor.  It has been proposed that 
hydrophobic residues on the core protein close to the linkage site are essential for the 
GlcNAcTI activity, which may attribute to the above mentioned discrepancy as the 
naphthalenemethanol group has a strong hydrophobic nature (33).   Nevertheless, 
biochemical studies directly using HSPG core proteins as the acceptors of EXTL2 and 
EXTL3 are necessary to test this hypothesis.  In addition, genetic studies targeting EXTL2 
and EXTL3 are essential to establish the specific roles of these two isozymes in initiation of 
HS biosynthesis.  It important to note that a recent study of the boxer (EXTL3) mutant in 
zebra fish suggested that abolishment of EXTL3 function causes severe reduction of HS 
biosynthesis, supporting the HS chain initiation function of EXTL3 (34).   
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Once committed to HS biosyntheis by installation of the first GlcNAc residue, the 
polymerization reaction proceeds by adding GlcUAβ4 and GlcNAcα4 residues, alternately 
(Fig. 5).  The enzymes encoded by the funding members of the EXT gene family, EXT1 and 
EXT2, have been demonstrated to act as HS polymerases (35-38).  EXT1 and EXT2 are both 
bifunctional enzymes, possessing both GlcUATII (distinguishing from GlcUATI that 
synthesizes the linkage region) and GlcNAcTII activities (Fig. 5).  EXT1 and EXT2 are not 
redundant enzymes, instead, they form a complex and both are indispensable for the 
biosynthesis of HS in vivo (36). The significance of heterocomplex formation in vivo is 
indicated by two lines of evidence.  First, the complex helps direct the EXTs to the Golgi 
apparatus rather than the ER (39,40); and second, the mutations of either EXT1 or EXT2 
could cause hereditary multiple exostoses, from which the name of the enzyme is originated 
(3) . Moreover, individual EXT isoform has markedly lowered HS polymerase activity 
comparing to the EXT1/EXT2 complex as determined by in vitro studies (41), providing 
additional evidence for the importance of complex formation.  It is important to note that 
EXT1 and EXT2 are not the only enzymes that possess GlcNAcT-II activity, EXTL1 and 
EXTL3 have also been demonstrated to be capable of adding GlcNAc residues to the 
growing HS chain in vitro (33).  But how the GlcNAcT-II activity of EXTL1 and EXTL3 
correlates to that of EXT1 and EXT2 is an intriguing question, especially considering that 
they do not possess any GlcUAT-II activity. One hypothesis is that EXTL1 and EXTL3 may 
play regulatory roles in HS biosynthesis as they may compete with the EXT1/EXT2 complex 
(33). However, direct evidence supporting this hypothesis has been lacking, and the real 
functions of EXTL1 and EXTL3 in HS polymerization must wait for future genetic studies 
targeting these two enzymes.  
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The crystal structure of EXTL2 has been solved in complex with the sugar donor 
UDP-GlcNAc, and in complex with UDP and the acceptor analogue GlcUAβ3Galβ-O-
naphthalenemethanol, providing an excellent model for understanding the mechanism of 
action of EXT family members (42).  However, since EXTL2 is the shortest isozyme of the 
family and it aligns to the C-terminal GlcNAcT domains of other EXT members, its structure 
only helps to understand the GlcNAcT activity of EXT(L)s.  Detailed biochemical study is 
needed to elucidate the functions of the N-termial domain of EXT(L)s.  For some enzymes, 
EXT1 and EXT2, the N-terminal domain harbors the GlcUAT activity (43), and for others, 
EXTL1 and EXTL3, its function is still a mystery.     
 
Chain modification 
Once polymerized, the HS backbone (N-acetylheparosan) is subjected to a series of 
modifications that exponentially diversify the structures of HS.  The GlcUA residues can be 
modified at two positions. The configuration at C5 position can be changed from S to R by 
HS C5-epimerase (C5-epi), giving rise to IdoUA residue; and both GlcUA and IdoUA can be 
sulfated at the C2 position by HS 2-O-sulfotransferase (2OST).  The modifications of 
GlcNAc residues take place at three positions.  The N-acetyl group of GlcNAc can be 
modified by N-deacetylase/N-sulfotransferase (NDST), a bifunctional enzyme that removes 
the N-acetyl group and installs a sulfate group; and the C3 and C6 position of glucosamine 
residue can be sulfated by HS 3-O-sulfotransferase (3OST) and HS 6-O-sulfotransferase 
(6OST), respectively  (Fig. 6).  
 
N-deacetylase/N-sulfotransferase 
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NDST is the enzyme that initiates modification of N-acetylheparosan.  N-sulfation of 
the glucosamine residue has been demonstrated to be essential for most of the subsequent 
modifications on the HS, thus representing a decisive step in the HS biosynthesis (3).  NDST 
does not modify the whole HS chain uniformly; instead, the N-sulfation tends to cluster 
together, giving rise to the NS domain of HS, distinguishing from the NA domain containing 
mostly the N-acetylated glucosamins (Fig. 6B) (2).   
The polypeptide chain of NDST can be divided into two domains, the N-terminal 
deacetylase domain (within the N-terminal ~600 residues) and the C-terminal N-
sulfotransferase domain (the last ~280 residues). Both domains have been expressed 
individually and been proven to contain their respective activities (44,45). In addition, NDST 
is a Golgi resident enzyme and contains a typical type II transmembrane region at the N-
terminal end.     
Four NDST isoforms has been identified in human and mouse (46-50).  The isoforms 
can be divided into two subgroups: NDST-1 and NDST-2 forms one group, sharing 70% 
amino acid identities, while NDST-3 and NDST-4 forms another group, sharing 80.4% 
identiy. The four NDST isoforms have distinct tissue specific expression patterns. NDST-1 
and NDST-2 are expressed quite uniformly in different tissue, while the expression of 
NDST-3 and NDST-4  occurs predominantly in the brain (46).  The NDST isoforms seems to 
have distinct deacetylase and sulfotransferase activities.  NDST-1 and NDST-2 have 
excellent deacetylase and sulfotransferase activities, with comparable levels of each.  NDST-
3 has good deacetylase activity but very poor sulfotransferase activity, and NDST-4 shows 
the opposite with poor deacetylase activity and excellent sulfotransferase activity.  The 
biological significance of the variations on the enzymatic activities of NDST isoforms is not 
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fully understood, but it has been proposed that it may help generate unique sulfation patterns 
on the HS (46).  
The crystal structure of the N-sulfotransferase domain (NST) of NDST-1 has been 
solved with PAP, which greatly expanded our understanding of the mechanism of action of 
this enzyme (44). In comparison to the crystal structure of estrogen sulfotransferase (EST), a 
cytosolic sulfotransferase, NST has an almost identical PAPS binding site harboring several 
well-conserved PAPS binding residues, while the substrate binding site is very dissimilar 
from that of EST.  The HS binding site of NST is a large open cleft with a hydrophilic 
surface, in contrast to the hydrophobic binding pocket for estrogen binding in EST.  In 
addition, a SN2-like in line displacement catalytic mechanism has been proposed for NST in 
light of a structural study using the existing NST structure and a modeled hexaccharide. The 
residue Glu642 has been suggested in this study to act as the catalytic base, which 
deprotonates the acceptor NH3+ group for a nucleophilic attack of the sulfur atom of the 
PAPS (51,52).  
A series of genetic studies of NDST-1 and NDST-2 has provides great insights into 
the physiological functions of N-sulfation in model animals.  The Ndst-1 null mice die 
shortly after birth due to severe lung failure (53,54).  In addition to prominent defects in lung 
development, detailed phenotypic study of Ndst-1deficient mice embryo at various 
developmental stages reveals they display conspicuous developmental defects at the 
forebrain, face and eyes (55), reinforcing the pleiotropic effects of NDST-1 in mammalian 
development.  The Ndst-2 null mice have also been generated, but in contrast to the wide-
spread effects of Ndst-1 mutant, the only obvious defect is observed in connective tissue-type 
mast cells (56,57).  These cells are generally active during inflammatory processes, and they 
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release various inflammation mediators such as mast cell proteases, histamine and heparins. 
However, in the mast cells of the NDST-2 deficient mice, production of heparin is aborted, 
the amount of histamine released is greatly reduced, and mast cell proteases are lacking. 
These data suggest that NDST-2 plays a predominant role in mast cells in terms of HS 
sulfation.  Conversely, since NDST-2 deficient mice develop normally otherwise, it seems 
that NDST-2 is dispensable in other tissues, where NDST-1 may play more dominant roles. 
Recently, NDST-1 has been knocked out in a tissue-specific manner in endothelial cells and 
leukocytes, which helped demonstrate the essential roles of HS in inflammatory responses 
(58).  
In comparison to the largely elucidated structure and function of the N-
sulfotransferase domain, the function of the N-terminal region of NDSTs is apparently 
understudied.  The N-terminal region, about 600 residues in length, contains N-deacetylase 
domain (45). However, we have extremely little knowledge about the deacetylase domain, as 
it has no homology to other carbohydrate deacetylase.  Thus the specific deacetylation 
mechanism is still elusive.  Understanding the deacetylation mechanism of NDSTs would be 
very informative, considering that varying NDST isoforms have distinct N-deacetylase 
activities,  and they may sculpture the HS backbone differently.  Elucidating this first step of 
HS modification pathway would give insight into how specific sulfation patterns are 
generated, as deacetylase essentially prepares the N-acetylheparosan for the subsequent 
sulfation reactions.     
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Figure 6. Schematic view of the HS modifications.  A. The HS modification enzymes and their 
respective modification sites are shown on the disaccharide units.  B. HS modification pathways.  The 
number of isoforms in human of each enzyme is shown in the parentheses after the name of the 
enzyme.  The sequence of the modifications shown only represents a general guide, and it is important 
to note the HS modification mode in vivo may display some variations from the main theme.  C. 
Representative disaccharide structures with specific biological functions.  
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Glucoronyl C5-Epimerase  
The first modification happens on the GlcUA residue is catalyzed by HS C5-epi, 
which interconverts the configuration of the C5 position, thus generating IdoUA residue (Fig. 
6A).  An N-sulfated glucosamine (GluNS) is required at the non-reducing end of the GlcUA 
for the action of C5-epi, suggesting the C5-epimerization rigorously follows N-sulfation (Fig. 
6B) (2).  Switching from GlcUA to IdoUA has been suggested to give HS a more flexible 
structure because it is known that IdoUA can adopt several pyranose ring confomations (1C4, 
4C1, and  2S0 skew boat), while GlcUA usually adopts 4C1 conformation (59).  In addition, 
IdoUA is a much more favorable substrate for HS 2OST, and the product IdoUA2S is 
essential for many biological functions of HS (60-64).  
Different from most other HS modification enzymes, only a single isoform of C5-epi 
is present in almost all species examined (with the exception of fish). C5-epi is a fairly large 
protein, with over 600 amino acids in most species, and the epimerase catalytic domain has 
been tentatively assigned to the C-terminal 220-230 residues based on alignment to 
homologous proteins and biochemical studies (64). A structural neighbor search reveals that 
the structure of C5-epi is more similar to polygalacturonic acid lyases than to other 
carbohydrate epimerases.  The crystal structure of one polygalacturonic acid lyase have been 
solved, which may aid in structure-function studies of the C5-epi (65).  
The C5-epi has been shown to form a complex with HS 2OST in vivo, which is 
indispensable for correct Golgi localization of C5-epi (27).  Formation of the complex may 
have a substantial effect on the enzymatic activity of C5-epi.  The common substrate for C5-
epi and HS 2OST, GlcUA, may be channeled through the enzyme complex to achieve a 
higher efficiency of modification, as it is known that IdoUA2S is no longer a substrate for 
      21
C5-epi (27,66).  The final ratio of the GlcUA/IdoUA presented in the HS may be actively 
regulated by this interaction.    
The knock-out mouse model of C5-epi has provided significant information about the 
physiological functions the enzyme (67). C5-epi deficient mice died immediately after birth 
due to respiratory failure, apparently as a result of poorly developed lungs.  Other evident 
phenotypes include undeveloped kidneys, eye defects, various skeletal abnormalities such as 
shorter body length and excessive mineralization.  Close examination of HS from C5-epi-/- 
mice shows that production of IdoUA is totally abrogated, while the proportion of  GlcUA2S 
increased 3 fold and the 6-O suflation increased 5 fold.  The phenotypic differences between 
the C5-epi-/- and NDST-1-/- mice suggests that C5-epimerization plays unique roles in animal 
development, and IdoUA or IdoUA2S are specifically needed for certain cellular signaling 
processes.    
A recent study pointed out that human C5-epi is transcriptionally regulated by the β-
catenin-TCF4 transactiviation complex, the terminal effector of the Wnt/ β-catenin signaling 
pathway(68). This study shows that there are two β-catenin-TCF4 cis-acting elements located 
in the enhancer region of the promotor, and ectopic expression of β-catenin and TCF4 
together significantly enhance the cellular level of C5-epi transcript, as well its enzymatic 
activity.  Based on the evidence that HS is an important regulator of the interaction between 
Wnt and its cell surface receptor Fz (Frizzled) (69,70), HS biosynthesis and Wnt signaling 
may be interdependent.  It raised the possibility that a feedback loop is present between an 
essential signaling pathway and specific cell surface HS structures, which may help achieve 
the fine control of the animal development.  Future study is needed to test the universality of 
this phenomenon in different cell types and in different species.  
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Uronosyl 2-O-sulfotransferease 
2-O-sulfation is the only sulfation occurs on uronic acid residues (Fig. 6A), and it is 
observed in HS originating from all metazoans.  For instance, more than half of the IdoUA 
found in mouse embryo are 2-O-sulfated, while only a minute portion of the GlcUA are 2-O-
sulfated (67).  In the adult tissues of Drosophila and C.elegans, about 30% and 20% uronic 
acids are 2-O-sulfated (71).  The 2OST is capable of reacting with both GlcUA and IdoUA 
residues, but prefers the latter under most conditions (Fig. 6B) (72).  
Very much like C5-epi, 2OST has only one isoform in most species, the exception 
also being fish.  2OST contains a type II transmembrane domain and is localized in the Golgi 
apparatus.  As described above, 2OST forms a complex with C5-epi in vivo, which is 
essential for the Golgi localization of C5-epi (27).  However, whether complex formation is 
indispensable for Golgi localization of 2OST remains unclear.  The complex may also 
influence the substrate specificities of 2OST in HS biosynthesis in vivo.   One can imagine 
that when C5-epi is complexed with 2OST, the majority of the resulting modification 
products would contain IdoUA2S.  When C5-epi is dissociated from 2OST, 2OST may be 
allowed to generate GlcUA2S, and C5-epi is able to generate IdoUA without sulfation.   
Thus, a possible role of C5-epi is to regulate the type of uronic acid that is subjected to 2OST 
modification.  Definitive demonstration of this possibility will require structural information 
from both 2OST and C5-epi, and the biological significance of the interaction should be 
tested in animal model systems.   
The HS 2OST knock out mouse has been generated; they suffer from neonatal death 
due to renal failure (73).  The 2OST-/- mice completely fail to form kidneys, show bilateral 
iris coloboma, and exhibit bone shortening and overmineralization. All of these 
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characteristics are similar to the phenotypes observed in the C5-epi-/- mice, suggesting 
essential roles of IdoUA2S in kidney, eye and skeletal development.  Surprisingly, 2OST-/- 
mice apparently develop functional lungs, a sharp contrast to the Ndst-1 and C5-epi knock 
out mice.  This difference indicates that 2-O-sulfation is not essential in lung development, 
but some IdoUA, as well as GlcNS are required.  Interestingly, close examination of the HS 
composition from 2OST-/- mice reveals that while 2-O-sulfated uronic acids are completely 
removed, the mice show elevated N-sulfation and 6-O-sulfation of glucosamine residues.  It 
has been proposed that the elevated sulfation at other positions of HS may attenuate the 
adverse effect imposed by the ablation of 2-O-sulfation, thus disguising some physiological 
functions associated with 2-O-sulfation.   
The 2OST null mutant has been described in C. elegans as well (74).  Surprisingly, 
C.elegans mutants deficient in 2OST are viable and fertile, and without any locomotory 
defect or embroyonic paralysis as observed in perlecan (a core protein of HSPG) deficient 
worms (75).  The phenotypes of 2OST null worms are only detectable in the nervous system 
development, displaying axonal guidance and migration defects in a neuron-type specific 
manner.  These findings suggest that the 2-O-sulfation of HS plays very specific roles in 
metazoan development.  These roles may vary in the developmental schemes of different 
species.  
The HS 2OST shows very little homology on the amino acid level to other HS 
sulfotransferase.  Therefore, rather unexpectedly, a structural neighbor search reveals that the 
catalytic site of HS 2OST appears more similar to that of hEST, which uses a histidine as a 
catalytic base rather than the glutamate that has been suggested to serve in this capacity in 
NDST and 3-OSTs (76,77).  However, 2OST is unique in that its catalysis seems to involve 
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two adjacent histidines, and only a double mutant H140A/H142A is able to abolish the 
activity, while single mutation of each is not suffient (78).  His142 of 2OST aligns with the 
catalytic base His107 of hEST, which is conserved among all cytosolic STs and many Golgi 
STs.  In comparison, His140 is a unique residue only presents in 2OST.  Without structural 
data, the precise roles of the two histidines are in sulfation by 2OST are unclear.  One 
possibility is that one histidine may function as a base while the other may help stabilize the 
transition state.  Mutational studies of 2OST suggest that this enzyme represents a distinctive 
branch of sulfotransferases.  Further structural studies of this enzyme may uncover novel 
mechanisms for HS recognition and catalysis in  HS-sulfation enzymes.    
 
Glycosaminyl 6-O-sulfotransferease 
6-O-sulfation of glucosamine residues is a prevalent modification of HS. The 
percentage of 6-O-sulftated disaccharide units ranges from 20-30% in different species 
(67,71). It occurs most often at the NS domain, generating a GlcNS6S moiety; but it can also 
occur at the NA domain, generating a GlcNAc6S moiety (79), which is notably the only 
sulfation occurs at the NA domain as both 2OST and 3OSTs depend on N-sulfation of 
glucosamine  (Fig. 6B) (3,80).  
Three isoforms of 6OST have been identified in human and they exhibit 
approximately 60% identity. (79).  These isoforms have highly conserved sulfotransferase 
domains, while varying in both N- and C-termini.  Several in vitro substrate specificity 
assays suggest that 6OST isoforms have distinct substrate preferences (79,81).  6OST1 
appears to favor the IdoUA-GlcNS unit significantly more than the GlcUA-GlcNS unit; 
while 6OST2 prefers GlcUA-GlcNS over IdoUA-GlcNS; and 6OST3 has almost equal 
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activities towards both disaccharide structures.  The three isoforms of 6OST are also present 
in other mammals and birds as well as amphibians, while invertebrates normally have only a 
single isoform of 6OST.    
Unlike the previously mentioned HS modification enzymes, a mouse knock out 
model for 6OST has not been reported.  Nonetheless, evidence from 6OST null Drosophila 
and C.elegans suggested that, like 2OST, 6OST plays significant roles in animal 
developmental processes (63,74,82,83).  Knocking out 6OST disrupts the development of the 
tracheal system—Drosophila analog of the vertebrate vascular system—is lethal for fruit 
flies.  Strong evidence indicates that this outcome is directly related to the essential function 
of 6-O-sulfated HS in fibroblast growth factor (FGF) signaling (63).  Interesingly, C.elegans 
6OST null mutants are viable and fertile, suggesting that 6-O-sulfation of HS is dispensable 
for worm FGF signaling.  However, very specific axonal guidance defects were seen in a 
neuron-type specific manner.  The effects of worm 6OST are believed to be related to several 
essential pathways in nervous system development, such as Slit/Robo system and Kal-1 
system (74,83).  
A morpholino-mediated functional knockdown study targeting zebrafish 6OST (58% 
identiy with human 6OST1 and 6OST2) provided a glimpse of the essential functions of 
6OST in vertebrate morphogenesis (84). The morpholino treatment decreased the overall 6-
O-sulfation level by merely 20%, yet several obvious phenotypes were observed.  The most 
notable defects of 6OST knockdown zebrafish embryo were seen in somite development, as 
embryo showed undifferentiated muscles and muscle degeneration.  Additional defects 
caused by 6OST knockdown were also identified in the brain and the fins.  It is now known, 
that zebrafish have at least one other 6OST isoform that is very homologous to human 
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6OST1 (81% identity) in addition to the 6OST that is knocked down in this study, which 
suggests that observed phenotypes may only represent a small fraction of the real impact of 
6-O-sulfation of HS on the zebrafish embryonic development.  
Based on a structural neighbor search, it is predicted that the structure of 6OST is 
similar to that of NST and 3OSTs, all of which modifying the glucosamine residues.  The 
overall fold of 6OST may be similar to that of NST and 3OSTs (Fig. 7), but unique structural 
features of 6OST family are noted.  6OST is unusual in that it contains ten cysteines that are 
fully conserved across isoforms and species, which forms a sharp contrast to 2OST (four 
conserved cysteines), NDSTs and 3OSTs (two conserved cysteines), and cytosolic 
sulfotransferase (no conserved cysteines).  Six of the ten cysteines are located between the 5′-
phosphate and 3′-phosphate binding sites of PAPS, where no cysteines appear in the above 
mentioned sulfotransferases (Fig 8).  The other four cysteines are located after the 3′-
phosphate binding site of PAPS, where the four cysteines of 2OST are similarly located (Fig 
8).  It is known that mutations of the cysteines in 2OST greatly decrease the protein stability 
(Ding Xu and Jian Liu, unpublished data), thus one may infer that the four cysteines in 6OST 
are also essential for protein integrity.   
Another intriguing structural feature of 6OST is that one of the splice variants of 
human and/or mouse 6OST2 has a 40 amino acid insertion immediate proceeding the 3′-
phosphate binding site of PAPS (Fig. 7) (81).  The longer variant of 6OST2 and the shorter 
display similar substrate specificities, but they apparently have distinct tissue-specific 
expression patterns.  This finding raised an interesting question about the structural role of 
the 40-residue insertion in the longer form.  One attractive hypothesis is that it may be 
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involved in regulation of 6-O-sulfation in a tissue-specific manner, possibly by interaction 
with other partner proteins.  
 
 
Figure 7. Structural features of 6OST.  Human 6OST1 is aligned to mouse 3OST3 based on the structure 
homology prediction (GenTHREADER).  The secondary structure of 3OST3 is displayed at the top of 
the alignment (76), while the predicted secondary structure of 6OST1 is displayed at the bottom in the 
following scheme: α-helices in red tubes, β-strands in green arrows, and coils in gray line. The 5′-
phosphate binding site (between β2 and α2) and the 3′-phosphate binding site (between β6 and α5) of 
PAPS are shown as dashed boxes.  Residues in 6OST1 that are homologous to the substrate binding 
residues in 3OST3 are shown in blue. Residues in 3OST3 that are essential for catalysis are shown in 
green, as is the potential catalytic base of 6OST1. Conserved cysteines in 6OST1 and 3OST3 are shown 
in red.  The amino acid present in the longer splice variant of 6OST2 is shown with a grey background.   
 
 
Glycosaminyl 3-O-sulfotransferease 
3-O-sulfation of glucosamine residues is generally considered the last step in the HS 
modification pathway, and understandably, the rarest one.  3-O-sulfation occurs 
predominantly in the highly sulfated regions of HS, as 3OST modified disaccharide units 
often contain multiple sulfations (Fig 7B) (1).  Due to its role in the final step in the HS 
modification pathway, 3OST usually dictates the unique functions of HS.  For instance, 3-O-
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sulfation is essential for the anticoagulant HS, and this single modification increases the 
anticoagulation activity for 18,000-fold (85).  As a result of extensive study on 3OSTs, 3-O-
sulfation of HS has been directly associated with many other biological processes such as 
viral infection (62), carcinogenesis (86), diurnal rhythm control (87) as well as animal 
morphogenesis (88).    
3OST represents the most extended gene family among all HS sulfotransferases.  
Veterbrates generally contain six isoforms of 3OST, while invertebrates tend to have two.  
The vertebrate 3OSTs can be divided into two subgroups based on the homology of the 
sulfotransferase domain. 3OST2, 3OST3, 3OST4 and 3OST6 form one subgroup (3OST3-
like subgroup), with higher than 70% of identity; whereas 3OST1 and 3OST5 forms another 
subgroup (3OST1-like subgroup), with 53% of identity.  The 3OST1-like and 3OST3-like 
subgroups exhibit approximately 45% of identity in the sulfotransferase domain.  Two 3OST 
isoforms, Hs3st-A and Hs3st-B, are identified In Drosophila (88). Interestingly, Hs3st-A is 
more homologous to human 3OST1-like subgroup, while Hs3st-B is more homologous to 
3OST3-like subgroup.  The same trend holds true for the two 3OST isoforms in C.elegans.  
These evidences suggest that it likely that the 3OST diverged into two branches early in the 
evolution to perform separate functions, and both branches expanded in vertebrates to carry 
out more diverse and specific roles.  
In comparison to the obscure substrate specificities of 6OSTs, members of the 3OST 
family have distinctive substrate specificities. 3OST1 synthesizes a characteristic 
disaccharide unit with the structure GlcUA-GlcNS3S±6S (Fig. 8) (89), which has been 
shown to be indispensable for the anticoagulant function of HS. 3OST2, 3OST3, 3OST4 and 
3OST6 all generate a characteristic disaccharide unit with the structure IdoUA2S-
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GlcNS3S±6S (Fig. 8) (10,12,90,91), which is absolutely required for HS that serves as the 
herpes simplex virus 1 (HSV-1) entry receptor.  3OST5 is unique in that it has very 
promiscuous substrate specificity.  It can not only generate both disaccharide units mentioned 
above, but also a disaccharide with the structure IdoUA-GlcNS3S±6S (Fig. 8), whose 
function is still unknown (11).  The distinct disaccharide units generated by 3OSTs provide 
indications about their biological functions, but it is important to note that the substrate 
specificities of 3OSTs are routinely analyzed at the disaccharide level, thus disguising the 
specificity differences at the oligosaccharide level, which may be important for many HS-
protein interactions.  
 
 
              
Figure 8. Schematic view of the substrate specificities of 3OSTs.    
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Only one isoform of 3OST, 3OST1, has been knocked out in mice (92). This study 
was originally aimed to determine the correlation between normal levels of anticoagulant 
active HS (HSact) and the antithrombin (AT)-regulated anticoagulation process.  However, 
the 3OST1-/- mice exhibit a surprisingly normal anticoagulation phenotype that is 
indistinguishable from the wildtype mice, in spite of the significant loss of HSact in various 
organs.  This study indicates that in spite of the potent anticoagulant property of heparin, the 
HSact is not a major hemostatic regulator like AT.  Nevertheless, the 3OST1-/- mice exhibit a 
genetic background-specific postnatal lethality.  The cause of the lethality is unknown, yet  is 
clearly distinct from the lethality caused by ATIII-/- mice.  This finding suggests that 3OST1 
modification of HS plays some profound roles in other biological processes, the details of 
which remain unclear.  
Studies in Drosophila provided the first direct evidence of the critical roles played by 
3OST in animal development (88). When Drosophila Hs3st-B was silenced by RNAi 
treatment, several morphological defects were observed.  These included severe rough eye 
phenotype, extra sensory bristles at multiple tissues and profound defects in wing 
morphology such as reduced wing size, abnormal wing veins and notching at the wing 
margin.  The phenotypic effects of Hs3st-B silencing have been related to Notch signaling 
directly, as Hs3st-B was shown to influence the protein level of Notch (cell surface receptor 
in Notch signaling).  The exact role of Hs3st-B modified HS in the Notch signaling pathway 
remains to be determined.  
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Figure 9.   A.  Stereo diagram of the HS binding site of 3OST3.  The tetrasaccharide substrate is shown 
in thin stick along with its electrostactic surface.  The side chains of the residues forming direct 
hydrogen bonds with the tetrasaccharide are shown in thick stick, and 3OST3 is illustrated as ribbon 
diagram in brown.   B. Stereo diagram of the catalytic active site of 3OST3. The sulfuryl group of 
PAPS is modeled in by superimposing the PAPS from the hEST-PAPS structure (1HY3) to the PAP in 
the 3OST3-PAP-tetrasaccharide structure.  The PAP (green) and the sulfuryl groups (yellow) are shown 
in stick, while the substrate GlcNS6S residue is shown in stick and ball.  The protein residues involved 
in catalysis are shown in stick and labeled.  Putative hydrogen bounds are displayed as black dashed 
lines. Possible interactions between 3OST3, the donor sulfuryl group and the acceptor site on the 
substrate are displayed as blue dashed lines.  The calculated distances of the possible hydrogen bonds 
are also labeled.   
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The crystal structures have been solved for the catalytic domain of two 3OST 
isoforms, 3OST1 and 3OST3 (76,77), providing a wealth of structural information for us to 
understand the sulfuryl transfer reaction carried out by this enzyme family.  The overall fold 
of 3OSTs sulfotransferase domain is very similar to that of NST-1.  The 3OSTs and NST-1 
share almost identical structure in the PAPS binding site, and they use a structurally 
homologous glutamate residue as the catalytic base (the catalytic site of 3OST3 is shown in 
Fig. 9B), which is not surprising given the similar spatial arrangements of the two 
modification sites (C2 and C3).  The major difference between 3OSTs and NST-1 exists in 
the HS binding cleft, where we found the 3OSTs contain a significantly higher concentration 
of positively charged residues relative to residues in the NST-1 HS binding cleft. The 
difference conceivably reflects the distinct substrate preferences of 3OSTs and NST-1, with 
the substrate of the former being much more negatively charged (77).   
A notable advance brought about by the structural study of 3OSTs is the 
determination of the ternary complex structure of 3OST3-PAP-tetrasccharide (76).  In this 
structure, multiple interactions between the 3OST3 and the substrate tetrasaccharide were 
observed, which gave insight into the mechanism by which different 3OST isoforms 
recognize and distinguish substrates (Fig. 9A).  Most of the residues in 3OST3 forming direct 
hydrogen bonds with the tetrasaccharide are conserved in 3OST1, but subtle differences 
between the two isoforms do exist.  These variable residues may contribute to differences in 
substrate specificity.   For instance, when Gln255 (Fig. 9A), interacting with the 2-O-sulfate 
group of IdoUA2S in 3OST3, is mutated to alanine, sulfotransferase activity was completely 
abolished; whereas when the structurally analogous residue in 3OST1, Gln163, is mutated, 
34% of enzymatic activity was maintained.  This results can be explained by the preference 
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of 3OST1 for GlcUA instead of IdoUA2S as part of the substrate recognition site.  In order to 
fully understand the substrate recognition mechanism of the 3OST enzymes family, more 
structures in complex with the oligosaccharide substrates are necessary.   
  
        Physiological Functions of Heparan Sulfate 
Anticoagulation 
Heparin is the most commonly used anticoagulant drug.  Heparin is an exclusive 
product of mast cells, and is released during degranulation of mast cells (93).  Therefore, HS, 
rather than heparin, is considered to be the “natural anticoagulant” in humans as HS is 
present on the surface of endothelial cells (94).  Both heparin and anticoagulant HS contain a 
structurally defined antithrombin(AT)-binding saccharide sequence, which is a 
pentasaccharide with the structure of –GlcNS(or Ac) 6S-GlcUA-GlcNS3S±6S-IdoUA2S-
GlcNS6S- (for structure see Fig. 10) (85,95).  The antithrombin-binding site is the essential 
motif conferring anticoagulant activity to heparin and HS.  Indeed, a synthetic AT-binding 
pentasaccharide demonstrates promising results on the prevention of deep-vein thrombosis 
(96).  In the AT-binding site, 3-O-sulfation of the glucosamine residue (to form GlcNS3S±6S) 
is the critical modification for binding to antithrombin.  It is known that a pentasaccharide 
without the 3-O-sulfation has decreased in the binding affinity, approximately 18,000-fold 
(85).  This critical 3-O-sulfation is carried out by either 3OST1 or 3OST5.   
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The essential physiological role of 3-O-sulfated HS (or aHS) in regulating blood 
coagulation has been demonstrated through the studies of AT and AT mutants.  A severe 
thrombosis phenotype is observed in mice carrying an AT mutant defective in heparin 
binding, suggesting a key role for HS-AT interaction in balancing procoagulant and 
anticoagulant activities in vivo (97).  Additionally, human patients with AT mutants defective 
in heparin and HS binding suffer from thrombosis (98-100).  Furthermore, it appears that 
complete ablation of AT-HS binding is required to reveal the full physiological role of 
anticoagulant HS in vivo (101).   Gene redundancy (to 3OST5) in the biosynthesis of aHS 
helps explain the failure of  3OST1 knockout mice to exhibit a prothrombotic phenotype (92). 
 
Inflammation 
Inflammation is usually the initial response of the immune system to tissue infection.  
It is a multi-step process involving chemokine generation at the infected tissue.  Chemokines 
transport into the luminal side of the endothelial cells, binding to leukocytes within the blood 
vessel.  The leukocyte-chemokine interaction results in leukocyte extravasation and 
migration towards the infected tissue.  Endothelial cell surface HSPG has been demonstrated 
           
Figure 10.  The structure of AT-binding pentasaccharide.  The 3-O-sulfation of the glucosamine 
residue (3-O-sulfation is in red) is the critical modification necessary for generating the antithrombin 
binding site.  GlcNS6S, GlcUA, GlcNS3S6S, IdoUA2S and GlcNS6S represent the abbreviations of 
the individual monosaccharide residues.  
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to play an essential role in the inflammatory response, as it is involved in most of the steps 
described above (102).  
Chemokines, a family of small proteins (8-10 kDa) secreted at the infected tissue by 
resident macrophages, have a principal role in recruiting leukocytes from the blood vessel to 
the site of inflammation.  It has been shown that chemokines are heparin binding proteins, as 
most of them are highly positively-charged proteins containing patches of basic residues at 
the heparin/HS binding site (103). The chemokine-HS interaction has recently been 
determined to be essential for presentation of chemokines on the luminal surface of the 
endothelial cells (104).  While a mutant chemokines defective in HS binding was able to 
activate leukocytes in an in vitro assay, the same mutant failed to activate leukocytes and 
induce cell migration in vivo, even at a concentration 10,000 times higher than the effective 
concentration used for wild-type chemokines.  This observation strongly supports a role for 
HSPG in enhancing the local concentration of chemokines, which would otherwise easily 
diffuse away in the presence of blood flow at the luminal surface of the endothelial cell near 
the site of infection.  In the same study (104), it was also suggested that GAG-mediated 
oligomerization may also promote the chemokine-induced inflammation activiation.  
In response to the initial inflammatory signal, leukocytes roll through the luminal 
surface of the endothelium, scanning for the infected site concentrated with chemokines.  It 
has recently been demonstrated that HSPGs are essential for the rolling process, and N-
sulfation of the HS are indispensable for this function (58).  In this study, mouse Ndst1 was 
conditionally knocked out in endothelial cells and leukocytes using the Cre-loxP system in 
order to study the specific functions of HSPG in inflammation.  The mutant mice showed 
significantly impaired inflammatory response in several in vivo assays.  This is partly due to 
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the weakened interactions between L-selectin, a ligand secreted by leukocytes, and the 
endothelial cell HSPG, as a result of the under-sulfated HS.  In the presence of under-sulfated 
HS, the rolling velocity of leukocytes would be too great to form adequate adhesion to the 
endothelium.  Moreover, chemokine endothelial presentation and transportation across the 
endothelium is also impaired in the NDST1 deficient mice, implicating an essential role of 
HSPG in these processes as well(58). 
Collectively, it has been established that HSPG is a potent inflammatory regulator, 
playing multiple roles in inflammatory responses.  The unique role of HSPG promises a 
therapeutic application of HS in treating inflammatory diseases.  Indeed, the anti-
inflammatory function of heparin has been exploited in several animal model studies as well 
as in human clinical trials targeting inflammatory bowel disease and asthma  (103,105), 
showing the great potential of HS as a novel anti-inflammatory drug.  
 
Angiogenesis 
Angiogenesis, a fundamental physiological process by which new blood vessels arise 
from pre-existing vasculature, is essential for embryonic development of the cardiovascular 
system and wound healing.  Due to its crucial roles in vertebrate development and 
homeostasis, as well as in tumor growth, angiogenesis is tightly controlled at multiple levels 
(106).  Stimulation of angiogenesis is regulated by the equilibria between pro-angiogenic and 
anti-angiogenic factors.  Among many other pro-angiogenic regulators, vascular endothelial 
growth factor (VEGF) and fibroblast grow factor 2 (FGF-2) are the two most potent and 
well-characterized, and both rely on HSPG to exert their angiogenic functions.  Surprisingly, 
HSPG has also been demonstrated to play a role in regulating the function of many anti-
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angiogenic factors, including endostatin, a proteolytic fragment of the C-terminal domain of 
the collagen XVIII(107).  
FGF-2 stimulates proliferation, migration, differentiation and survival of the 
endothelial cells, greatly influencing angiogenesis.  The full potential of FGF-2 is realized 
via through its interaction with an abundant basement membrane (BM) HSPG, perlecan.  
Studies have shown that perlecan acts as a low-affinity receptor for FGF-2 (108), which is 
essential for binding of FGF-2 to its high-affinity FGF receptors (FGFRs).  Binding of FGF-2 
to the HS chain of perlecan is likely to promote its dimerization, as well as formation of a 
ternary complex with two molecules of FGFR, which themselves have direct interaction with 
HS (109).  The crystal structure of a ternary complex between two FGF-2:FGFR-1 dimers 
and heparin has been solved, providing strong evidence that heparin/HS play an active role in 
the binding between FGF-2 and FGFR-1 (110) (111).  Based on the structural information 
and biochemical studies (109,112), it has been determined that 2-O-sulfation of IdoUA and 
the 6-O-sulfation of GlcN are of great importance in terms of assisting the formation and 
activation of the FGF-2:FGFR complex.   
VEGF is a potent pro-angiogenic factor, and in contrast with all other angiogenic 
factors, its growth stimulating function is restricted almost completely to endothelial cells 
(106).   VEGF regulates angiogenesis through its interaction with the two VEGF receptors 
(VEFGR), and the HS moiety of glypican-1 has been shown to greatly potentiate the 
interaction.  N-, 2-O- and 6-O-sulfations of HS have been shown to contribute to the 
interaction with VEFG, with the 6-O-sulfation being the essential sulfation (113). The 
importance of the 6-O-sulfation in the VEFG mediated angiogenesis has been implicated in a 
zebrafish gene knockdown study, where one of the zebrafish 6OST is silenced by morpholino 
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treatment and the mutant fish exhibit a decreased vascular branching phoenotype (114). The 
VEGR, VEGFR and HSPG may form a ternary complex in a similar fashion to the FGF-
2:FGFR-1:HSPG complex (106), as it is known that VFGFRs are also heparin binding 
proteins (115).   
Endostatin originates from the C-terminal tail of collagen XVIII, a ubiquitous 
basement membrane (BM) HSPG with HS attached to the N-terminal and middle triple-
helical domains (116).  Endostatin inhibits the FGF-2 or VEGF induced endothelial cell 
proliferation and migration (117,118), and it has been shown to keep tumor angiogenesis in 
check when delivered into mice bearing primary tumors (119).  It was reported that cell 
surface glypicans greatly promote the functional interaction between endostatin and its 
receptor, intergrin α5β1(120,121).  From the crystal structure of mouse endostatin, a highly 
positively charged patch is easily identified, which possibly serves as the HS binding site.  
Mutational study of this region suggested it is involved in the anti-angiogenic function of 
endostatin (116) .  
 
Development 
The critical roles of HSPG in animal development are demonstrated in many model 
organisms.  Animal development is incompatible with the total depletion of the HS chain, as 
it has been shown that removing the HS polymerization enzyme EXT or its analogue in mice, 
flies and worms causes embryonic lethality (122).  More organ-type specific developmental 
defects were observed in animals that are absent of or deficient in HS modification enzymes, 
as seen in Ndst1, Hs2st and C5-epi knockout mice (53,54,67,73); Hs6st knockdown zebrafish 
(84); hs2st, hs6st knockout (63) and hs3st-B knockdown fruitflies (88) ; hse-5, hst-2 and hst-
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6 knockout C.elegans (74). Collectively, these model system studies unambiguously support 
the general significance of HSPG in animal development, while the specific functions of 
HSPG in animal morphogenesis mainly come from genetic studies in Drosophila. 
During animal development, cells differentiate according to spatial information 
presented by the concentration gradients of morphogens, secreted protein ligands that 
activate specific intracellular signaling pathways (123).  Accumulating evidence suggests 
that cell surface HSPG, particularly glypicans, has profound effects in gradient formation and 
maintenance of Wg and Hh, two of the most substantial morphogens in animal pattern 
formation.  Wg and Hh pathways work collaboratively and play predominant roles in 
embryonic segment polarity determination.  In HS biosynthesis defective mutants, the Hh 
diffusion is limited to adjacent cells, while in WT flies it can travel over long distance and 
activate targets that are 5-6 cell diameters away (124).  In the case of Wg, the extracellular 
concentration of Wg is reduced and the target gene expression is abrogated when several HS 
biosynthetic enzymes, such as NDST and EXT, or glypican core proteins are absent (125).   
Recently, FGF signaling has been determined to rely on the 6-O- and 2-O-sulfation of 
HS in the tracheal system (fly analogue of the vertebrate vascular system) development in 
Drosophila (63).  In this study, it was discovered that either of the Hs2st and Hs6st null 
alleles had very mild perturbations in the tracheal system development, likely due to the 
sulfation compensation effect.  In comparison,  when combined, Hs2st/Hs6st double mutants 
are completely lethal.   Detailed examination of the downstream factor MAPK of the FGF 
signaling pathway suggested that MAPK activation was disrupted in the double mutants 
while the FGF expression level was apparently not affected, suggesting that the ablation of 6-
O- and 2-O-sulfation of HS at the cell surface impeded FGF signal reception.  
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Aside from shaping the ECM morphogen gradient, additional roles of HSPG in 
development have also been reported.  An RNAi-mediated knockdown of Hs3st-B, one of the 
two 3OST analogs in Drosophila, displays phenotypic defects that are typical of Notch 
signaling mutants (88).  The Notch pathway is one of the fundamental pathways deployed in 
animal development. The major difference between Notch and Wg/Hh pathways is that the 
former works mainly between the adjacent cells because both Notch, the receptor, and 
Delta/Serrate, the ligands, are transmembrane proteins.  The function of Hs3st-B has been 
assigned to upstream of Notch activation, and some evidence suggests that 3-O-sulfated HS 
may be directly involved in the Notch maturation and presentation to the cell surface.  
Further study is needed to elucidate the exact function of HS in Notch trafficking, and if 
proved, this will represent a totally novel function of HS in signal transduction.   
 
Neurogenesis 
Neurogenesis, the development of nevous system, is an integral part of metazoan 
development.  Neurogenesis is similar to general morphogenesis in that both are controlled 
by the secreted or cell surface signals. However, more specialized signaling pathways tend to 
be deployed in neurogenesis.  The involvement of HSPG in neurogenesis has been reported 
in all major model organisms (126), and the accumulated evidence indicates that HSPG is a 
key modulator of axon path-finding in the complex extracellular environment.   
The nervous system specific effects of HS were studied in mice by using a neural-
specific conditional Ext1 knockout (127).  A gross brain patterning defects were observed,  
including  significantly smaller cerebral cortices, missing olfactory bulbs, and a lack of 
boundary between the midbrain and hindbrain.  More detailed examination of the nervous 
      41
system showed the knockout mice had substantial defects in axon guidance.  The function of 
HSPG in axon guidance has been associated directly with the Slit/Robo signaling pathway, a 
pathway used extensively by many neuron types in axon path-finding. Ext1 and Slit mutants 
have genetic interactions as Slit2-/-; Ext1+/- compound mutants display axon guidance defects, 
which were not seen in either Slit2-/- or Ext1+/- single mutant alleles (127).  Further evidence 
for the essential role of HSPG in regulation of the Slit/Robo pathways were also reported in 
zebrafishs, fruit flies and worms (34,74,128).  
A more detailed understanding of the correlation between axon guidance and specific 
HS modifications came from the genetic study of C.elegans targeting worm analogs of C5-
epi (hse-5), 6OST (hst-6) and 2OST (hst-2) (74).  Each of these worm mutants displayed 
overlapping yet distinct axon guidance defects in a neuron-type specific fashion. This clearly 
demonstrates that not only the physical presence of HS is required for axon migration, but 
also the defined epimerization and sulfation patterns in the HS chain.  Slit/Robo and KAL-1 
pathways directly involve the HS-modification specific phenotypes of axon guidance (74).  It 
seems that C5-epimerization, 6-O- and 2-O-sulfation of HS are all required for Slit/Robo 
system in certain neuron types, while C5-epimerization but not 2-O-sulfation is required for 
the neuron type affected by Kal-1 system.  A fascinating discovery from this study is that 
different neuron classes vary in their dependence on HS modifications, even when their axon 
migrations are mediated by the same signaling system.  For instance, in one type of neuron, 
all three modifications are needed for correct axon routing regulated by Slit, whereas in 
another type, none of the three is needed for Slit function.  This pioneering study will 
undoubtedly lead to more sophisticated examination of the complex roles of specific HS 
modifications in modulating axon guidance in various model systems.  Indeed, a very recent 
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study has shown specific axon guidance defects in the mice optic chiasm generated by Hs2st 
and Hs6st knockouts (129).  
 
 
     Pathophysiological Functions of Heparan Sulfate 
Viral infectious disease 
In order to establish an infection, viral particles must first make close contacts with 
the host cells.  Naturally, the macromolecules presented at the cell surface, including HSPG, 
become the primary depots for virion attachment.  Since almost all human cells produce 
HSPG, and HSPG is present in huge abundance at the cell surface, it not surprising that many 
types of viruses have adopted unique methods to interact with HSPG. These includes some 
life-threatening viruses such as human immunodeficiency virus (HIV) and hepatitis C virus 
(HCV); as well more widespread viruses such as herpes simplex virus (HSV) (1).  HSPG has 
been shown to play an essential role in the infection mechanisms of these viruses, and 
sometimes, the involvement of HSPG goes beyond the initial virion attachment step.  
The multifaceted functions of HS in viral infection are most well characterized for HSV-1, 
which can cause keratitis, facial mucocutaneous lesions, and less frequently, life-threatening 
encephalitis in humans (130).  It is well known that HS serves as the initial binding receptor 
of HSV-1. Two HSV-1 envelope glycoproteins, glycoprotein B (gB) and glycoprotein C (gC), 
have been suggested to play central roles in the initial attachment step (130). Absence of both 
gB and gC severely reduces the attachment of HSV-1 to the cell surface. Structural studies of 
the HS involvement in gC binding suggested that a saccharide sequence containing IdoUA2S 
and GlcNS(orAc)6S is required for the interaction (131,132).  Glycoproteins homologous to 
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either gB or gC are present in other types of herpesviruses, suggesting the prevalence of this 
binding mechanism in the family (130).   
Once the attachment is established, enveloped viral particles must induce fusion 
between the viral envelope and the cell membrane in order to enter the cell plasma. This step 
is in many cases mediated by interactions between viral envelope proteins and the cell 
surface receptors (entry receptors) that are harnessed by viruses for their own use (130).  
HSV-1 has been determined to utilize three types of entry receptors, including HVEM, a 
member of the TNF-receptor family; nectin-1 and nectin-2, two members of the 
immunoglobulin family; and unexpectedly, HS with a specific structure containing 3-O-
sulfation (130).  An HSV-1 envelope glycoprotein gD has been proven to be the viral ligand 
for these entry receptors, and it binds to all three receptors in the low micromolar range.  The 
HS serving as the HSV-1 entry receptor was determined to contain a signature disaccharide 
sequence, IdoUA2S-GlcNS(NH2)3S±6S.  This structure can be found in 3OST3 modified 
HS while it is absent from 3OST1 modified HS.  It is important to note that the sequence of a 
gD-binding octasaccharide isolated from a 3OST3 modified HS oligosaccharide library was 
determined to be ΔUA-GlcNS-IdoUA2S-GlcNAc-UA2S-GlcNS-IdoUA2S-GlcNH23S6S 
(133).   It was later reported that 3OST2, 3OST4, 3OST5 and 3OST6 are all capable of  
generating this characteristic disaccharide structure; and the modified HS is able to mediate 
HSV-1 entry in the in vitro cell assay (11,12,134,135).  The first evidence that the 3OST3 
modified HS may play a role in keratitis was recently reported (13).  Primary culture of the 
corneal fibroblasts from a human patient has been found to express 3OST3 and contains the 
3OST3-modified HS serving as HSV-1 entry receptor.    
      44
Moreover, some evidence suggested that 3-O-sulfated HS may also play a role in the 
spread of HSV-1.  One method employed by viruses to spread from one cell to another is by 
inducing fusion between the infected cells and neighboring cells.  Similar to the virus entry 
process, this event is mediated by envelope glycoproteins and entry receptors.  3OST2, 3, 4, 
5 and 6 modified HS has all been determined to assist the fusion process (12,134-136), thus 
promoting the spread of HSV-1.  
 
 
Figure 11. Schematic view of the interactions between a HSV-1 viral particle and the cell surface 
binding receptor (HS) and entry receptors (HVEM, nectins and 3-O-sulfated HS).   
 
HSPG has been demonstrated to play several roles in assisting HIV infection.  The 
infection of HIV is initiated by binding of the viral envelope glycoprotein, gp120, to cell 
surface attachment receptors, including CD4 and HS.  Several cell lines showed reduced 
attachment and infectivity of HIV after heparinase treatment or using HS as a competing 
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agent, suggesting important roles of HS in the HIV infection pathway (1).  A recent study 
showed the interaction between HS and gp120 goes beyond simple attachment.  A surface 
plasmon resonance (SPR)-based study indicates that gp120 displayed dramatically increased 
binding affinity to HS after association with CD4, which is known to trigger a 
conformational change in gp120 (137). Accompanying molecular modeling studies suggested 
exposure of an additional HS binding motif after the conformational change, therefore 
contributing to enhanced binding affinity.  This finding implicated that HS may play more 
sophisticated roles in HIV infection, because it is known that the predicted additional HS 
binding sites exposed by the conformational change serves as binding epitopes for HIV entry 
receptors.  
Collectively, accumulating evidence indicates that cell surface HSPG is involved in 
multiple stages of the infection pathways of various clinically relevant viruses.  Targeting 
HSPG may be a novel therapeutic method for treating these viral infectious diseases by 
preventing the attachment of the viruses to the cell surface or by blocking virus entry and 
spreading processes.  
 
Tumor progression 
Tumor formation and growth may be conceived as a consequence of the deregulated 
cell proliferation that disrupting the normal homeostatsis.   Tumor usurps many basic 
regulation mechanisms that play key roles in general developmental process, disregarding 
normal growth constraints (138).  Since HSPG has been demonstrated to exert multiple 
functions in many physiological events including development and angiogenesis, it is hardly 
surprising that HSPG is one of the key players on the stage of tumor progression.  All tumor 
cells display HSPG on their surfaces. However, expression, fine structure regulation,  and 
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degradation of HSPG are now regulated by conditions that favor tumor proliferation and 
progression.  To date, HSPG has been shown to be involved in the transformation, 
proliferation and metastasis of tumor cells as well as angiogenesis that supplies the growing 
tumors with mutrients (139).  
It has been reported that several malignant tumors have aberrant expression profiles 
of HSPG synthesis genes, implicating that HSPG is involved in oncogenic transformation.   
In uterine carcinoma and multiple myeloma, syndecan-1 has been found to be downregulated, 
and its expression decreases during the transition from in situ carcinoma to invasive 
carcinoma (140).  Similarly, the glypican-3 (encoded by GPC3) is downregulated or silenced 
in breast and ovarian carcinomas, and in mesotheliomas, likely as a result of 
hypermethylation at the promoter region of GPC3 (141).  Evidence also exists for high-
incidence downregulation of an HS modification enzyme, 3OST2, in several tumor types 
examined, including breast (88%), colon (80%), lung (70%) and pancreatic (100%) 
carcinomas (86).  The downregulation of 3OST2 expression is mediated also by 
hypermethylation at the promoter region.  This discovery suggests that decreasing the 
cellular activity of 3OST2, and presumably specific HS structures generated by the enzyme, 
would favor the progression of a wide variety of tumors. Therefore, 3OST2 may be an 
important tumor suppressor gene.   This information provides an excellent lead to investigate 
the influence of HS fine structures on tumor formation and progression.  It would be very 
exciting to see future genetic studies targeting 3OST2 in mouse models, which would shed 
light on the correlation between this enzyme and carcinogenesis.   
It is known that cell surface HSPG has been widely deployed as a storage depot of 
numerous growth factors (GFs).  HSPG regulates the bioavailability of GFs by increasing 
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their local concentration, protecting them from degradation and potentiating their interactions 
with respective receptors.  One of the hallmarks differentiating tumor cells from normal cells 
is that tumor cells gain self-sufficient proliferation signals (138), and it appears that tumor 
cells conveniently take advantage of the ability of HSPG to facilitate sustained supply of 
tumor-released GFs for autocrine effects and paracrine effects on neighboring cells (139).  In 
one case, it was shown that a unique HS modulation enzyme, SULF1, which removes 
specific sulfation groups from HS, is downregulated in breast, hepatocellular, pancreatic and 
many other cancers (142).  It is demonstrated that by suppressing the activity of SULF1, 
tumor cells can generate higher numbers of FGF2, HB-EGF (heparin-binding epidermal GF) 
and HGF (hepatocyte GF) binding sites on HS, thus potentiating the mitogenic responses.   
In order to provide energy to the increasing mass, tumor cells must harness the 
angiogenesis regulation system.  HSPG is known to be a potent regulator of angiogenesis via 
interaction with numerous pro- and anti-angiogentic factors.  A large body of evidence 
suggests that HSPG is extensively involved in tumor angiogenesis.  It has been shown that 
antisense targeting of perlecan, which is known to interact with FGF2 and VEFG, blocks 
tumor angiogenesis and carcinoma growth in mouse models (143).  In another recent study, it 
is reported that in an NDST-1 endothelial-specific knockout mice model, the tumor cells 
exhibit noticeably diminished angiogenesis (Fuster, M et al. unpublished results).  It is 
important to note that targeting tumor angiogenesis is widely considered an advantageous 
chemotherapeutic strategy for cancer treatment, because the targets of this therapy, 
endothelial cells, are genetically much more stable than tumor cells and less likely to develop 
resistance.  The multifaceted roles of HSPG in the angiogenesis will expectedly make it a 
very tempting target of this anti-cancer therapy.  
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During tumor growth, the ECM network is constantly remodeled to accommodate the 
increasing cell mass and facilitate tumor invasion, eventually leading to metastasis.  This is 
performed by many tumor-secreted matrix-degrading enzymes including heparanase, an 
endoglycosidase that specifically cleaves the HS.   Heparanase is expressed in carcinoma, 
melanoma and lymphoma cells, and there is a positive correlation between the heparanase 
expression and enhanced tumor invasion and metastasis.  At the invading tumor front, 
heparanase not only degrades HS, making way for tumor progression, but also releases 
sequestered GFs and VEGFs, promoting tumor growth and supporting formation of tumor 
neovasculature (139).  These features make heparanase an attractive target of anti-tumor drug 
development.  Indeed, various forms of heparin have been shown to be effective in inhibiting 
tumor heparanase activity and tumor invasion in vivo (139).  Substantial effort has been 
devoted to developing heparanase inhibitors, including HS mimics, small molecule inhibitors, 
and antibodies.  Noteworthily, PI-88, a highly sulfated phosphosulfomannan mixture ranging 
in size from di- to hexasaccharide, is currently being evaluated in clinical phase II trials in 
patients with various cancers and showes promising anti-angiogenic effects and reduced 
invasiveness of carcinomas (144).  
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Statement of Problem 
HS has been demonstrated to play important roles in multiple physiological and 
pathophyiological processes, and it promises a bright future of therapeutic applications for 
various diseases.   The diverse functions of HS rely on its diverse structures, resulting from 
modification by many HS biosynthetic enzymes.  A more detailed understanding of how 
specific structure patterns of HS are generated by numerous HS modification enzymes is one 
of the major interests of the HS field.   In higher organisms, many HS modification enzymes 
exist in multiple isoforms, and it is widely accepted in the field that these isoforms play 
significant roles in determining the fine structures of HS.  In order to have a complete view 
of the HS biosynthesis, all existing isoforms must be identified and characterized.  The first 
goal of this research was to characterize the substrate specificity and biological function of 
the last member of 3OST gene family, 3OST6.  
In order to fully understand how specific structures are generated by HS biosynthetic 
enzymes in a non-template driven manner, a key issue to be addressed is how the HS 
biosynthetic enzymes recognize the unique structures of their respective substrates.  Thus, the 
goal of my second and third projects was to investigate the structure-function relationship of 
several HS modification enzymes by combining crystal structure determination and 
biochemical mutation studies.  The enzymes of interest are 3OST5, the only promiscuous 
isozyme in the 3OST family, which we want to co-crystalize with two different HS substrates; 
and 2OST, an enzyme that primarily generates the IdoUA2S moiety that plays significant 
roles in many signaling pathways in animal development.   
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                            Chapter II. Materials and methods 
 
 
Disaccharide Analysis of [35S]HS 
The [35S]HS isolated from metabolically labeled cells (or resulted from HS 
sulfotransferase modification with [35S]PAPS) was degraded with nitrous acid at pH 1.5 
followed by reduction with sodium borohydride. The resultant 35S-labeled disaccharides were 
desalted on a Bio-Gel P-2 column (0.75 x 200 cm) that was equilibrated with 0.1 M 
ammonium bicarbonate at a flow rate of 4 ml/h. The disaccharides were resolved by a C18-
reversed phase column (0.46 x 25 cm) (Vydac) under the reverse-phase ion-pairing HPLC 
(RPIP-HPLC) condition.  Briefly, the column was eluted with acetonitrile as follows: 8% for 
30 min followed by 15% for 15 min and followed by 19.5%, in a solution containing 38 mM 
ammonium phosphate monobasic, 2 mM phosphoric acid, and 1 mM tetrabutylammonium 
phosphate monobasic (Fluka) at a flow rate of 0.5 ml/min.  The identities of the disaccharides 
were determined by coeluting with appropriate 3H-labeled and 35S-labeled disaccharides (10). 
 
Determination of the Binding of HS to antithrombin (AT) 
The AT binding of [35S]HS was performed by using an AT/concanavalin A (ConA)-
Sepharose approach (145).  Briefly, [35S]HS (10,000–100,000 cpm) was incubated in 150 µl 
of a buffer, which contains 10 mM Tris-HCl, 150 mM NaCl, 1 µM dextran sulfate, 1 mM 
Ca2+, Mg2+, and Mn2+, and 0.1 mg/ml AT (pH 7.5), at room temperature for 30 min.  The 
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solution was mixed with the prewashed ConA-Sepharose (60 µl of 1:1 slurry) and agitated at 
room temperature for 1 h.  The gel was then washed with 3 × 1 ml of a buffer containing 10 
mM Tris-HCl, 0.0004% Triton X-100, and 150 mM NaCl (pH 7.5).  The HS was eluted from 
the gel by 1 ml of a buffer containing 10 mM Tris-HCl, 1000 mM NaCl, and 0.0004% Triton 
X-100 (pH 7.5). 
 
Determination of the Binding of HS to gD 
The assay for determining the binding of [35S]HS to gD was carried out by an 
immunoprecipitation procedure using anti-gD monoclonal antibody(62).  The [35S]HS 
(100,000–200,000 cpm) was incubated in 50 µl of a buffer containing 50 mM Tris-HCl, 150 
mM NaCl, and 0.01% Triton (pH 7) (binding buffer), and 2 mg/ml of gD at room 
temperature for 30 min.  The anti-gD monoclonal antibody DL6 (5 µl) was added and 
incubated at 4 °C for 1 h followed by the addition of protein A-agarose gel (80 µl of 1:1 
slurry) and agitated at 4 °C for an additional hour. The HS was eluted from the gel with 1 ml 
of 1 M NaCl in binding buffer. 
 
Stable transformation of CHO cells with 3OST6 
The expression plasmid pcDNA3.1-3OST6-myc-His was transfected into wild-type 
CHO cells using LipofectAMINE 2000 (Invitrogen) following the manufacturer’s protocol.  
Six days after the transfection, the cells were trypsinized and transferred into a 6 × 8-well 
plate at the concentration of 0.5 cells per well.  The cells were grown in F12 medium 
containing 10% fetal bovine serum and 1 mg/ml Geneticin at 37 ºC under 6% CO2 for 2 to 3 
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weeks until the confluency was attained.  The clone with highest expression level of 3OST6 
was identified by western blot analysis as described below.  
 
Western blot analysis of the expression of 3OST6 
Cellular extracts from CHO-K1 and 3OST6/CHO cells were prepared by using a 
procedure described elsewhere (11).  About 300 µg of cell extract was resolved on 13% SDS-
PAGE and transferred onto nitrocellulose membrane (Amersham Pharmacia Biotech).  One 
µg ECL-protein molecular weight markers (Amersham Biosciences) labeled with biotin was 
used as the MW marker.  The product was detected by using mouse anti-myc antibody 
(Invitrogen) followed by horseradish peroxidase conjugated anti-mouse IgG secondary 
antibody (Amersham Biosciences).  ECL Western Blotting Detection Reagents (Amersham 
Biosciences) was used to induce chemilluminescence and the blot was exposed to X-ray film 
(Kodak) for 15 minutes 
 
Metabolically labeling 3OST6/CHO cells and preparation of  [35S]HS 
CHO-K1 and 3OST6/CHO cells were grown to 60-70% confluency in T-75 flasks.  
After removal of growth medium, cells were incubated with 5 ml labeling medium for 10 
hours at 37ºC.  The components of labeling medium are as following: F-12 medium, 10% 
dialyzed fetal bovine serum, 1 mCi/ml Na2[35S]SO4.  Then, 1 ml of 1 mg/ml pronase (Sigma) 
in a buffer containing 240 mM NaAcO (pH6.5) and 1.92 M NaCl was added into the labeling 
media to lyse cells.  The mixture was incubated at 37ºC overnight.  The resultant samples 
were subjected a 1 ml DEAE-Sephacel column.  The column was washed with 10 ml buffer 
A (20 mM NaAcO, pH5, 150 mM NaCl) and eluted with 5 ml buffer B (20 mM NaAcO, pH5, 
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1 M NaCl).  The eluent was dialyzed against 50 mM ammonium bicarbonate using 14,000 
molecular weight cut-off (MWCO) membrane and dried.  The samples were reconstituted in 
1 ml H2O and subjected to β-elimination under alkaline condition at 46ºC for 16 hours.  The 
samples were then subjected to phenol/chloroform extraction to remove protein.  [35S]HS 
was precipitated by 75% ethanol.  Minor amount of chondroitin sulfate may remain in the 
sample, but it did not interfere with the subsequent disaccharide analysis. 
 
Northern blot analysis of 3OST6 
The coding sequence of 3OST6 was used as a template to prepare the 32P-labeled 
probe using Random Primer Kit (Stratagene) and [α-32P]dCTP to hybridize the Mouse 
Multiple Tissue Northern (MTN) blot (CLONTECH). The hybridization was carried out in a 
standard hybridization buffer (5 × SSC, 5 × Denhardt’s solution, 0.5% SDS) at 68 °C 
overnight, and the blot was washed with 2 × SSC containing 0.05% SDS at room tempeture 
for 2 × 30 min (where 1 × Denhardt’s solution contains 0.2 mg/ml Ficoll, 0.2 mg/ml 
polyvinylpyrrolidone, 0.2 mg/ml bovine serum albumin; 1 × SSC contains 150 mM NaCl and 
15 mM sodium citrate, pH 7.0), followed by washing with 0.1 × SSC containing 0.1% SDS 
at 50 °C for 2 × 40 min. The membrane was exposed to an X-ray film (Kodak) for 5 days. 
 
GroEL/ES chaperonine assisted E.coli expression system  
Preparation of CHAPOrigami-B competent cells 
Origami-B cell (Novagen) was transformed with pGro7 plasmid (Takata) containing 
the coding sequence for E.coli GroEL/ES to generate ChapOrigami-B cell.  3 ml culture 
supplemented with 15 µg/ml tetracycline, 15 µg/ml kanamycin and 35 µg/ml 
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chloramphenicol was inoculated with ChapOrigami-B cells .  After overnight (O/N) growth at 
37 oC, 1 ml of the saturated culture was used to inoculate 100 ml of sterile LB medium 
(without any antibiotic). The cells were incubated at 37 oC with shaking at 220 rpm, until 
OD600 reached 0.5; approximately 3.5-4.5 hrs for Origamin-B.  The flask was chilled on the 
ice for 15 min, then collect the cells by centrifugation at 6000 rpm for 10 min at 4oC. The cell 
pellet is resuspended in 10 ml of ice-cold TSS (Transformation and Storage Solution for 
chemical transformation) solution by repeated pipeting, until no cell pallet was visible.  
The TSS solution has the following components: 85 % LB medium, 10 % PEG 
(wt/vol, MW 8000), 5 % DMSO (vol/vol), 50 mM MgCl2 (pH 6.5). The solution is then 
sterilized by syringe filtration (0.45 um filter).  This solution should be prepared freshly each 
time.  
 
Expression of target protein in CHAPOrigami-B cells 
CHAPOrigami-B cells were transformed with the protein expression vector following 
conventional methods.  A single colony was inoculated into LB medium supplemented with 
15 µg/ml tetracycline, 15 µg/ml kanamycin, 35 µg/ml chloramphenicol, and 50 µg /ml 
carbenicillin ate 37 °C.  When the OD600 reached 0.4–0.6, the shaker temperature was 
reduced to 22 °C to allow the culture to cool down. IPTG and L-Arabinose was added to a 
final concentration of 0.1 mM and 1 mg/ml, respectively. Then the cells were allowed to 
shake overnight at 22 °C. 
 
Protein property analysis by gel filtration on HPLC   
Gel filtration chromatography using HPLC affords a fast (less than 15 min) and 
accurate way to determine many properties of recombinant proteins such as oligomeric state 
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and solubility potential.  For oligomeric state determination, about 100-200 µl  eluent from 
the affinity column is centrifuged at 14,000 rpm to remove any small particles or protein 
precipitation and injected onto an G3000SWXL (Tosoh Bioscience) gel filtration column pre-
equilibrated with running buffer (20mM Tris or MOPS, 400mM NaCl, pH 7).  The column is 
washed with running buffer at 1 ml/min, and the chromatogram is recorded by UV 
absorbance at 280 nm.  The approximate molecular weight (MW) of the target protein is 
determined by comparison to MW standards.  
For protein solubility potential measurement, eluent from the affinity column is 
concentrated sequentially to 2×, 4×, 8× of the original concentration.  Then 100 µl of sample 
at each concentration is loaded onto the G3000SWXL column and HPLC is performed as 
described above.  If the solubility limit of a target protein is not reached, one should see peak 
area increasing in proportion to the concentration. Conversely, if the solubility limit of a 
target protein is reached, one may observe that at a certain concentration the peak area fails 
to increase proportionally, and the solubility limit of the protein can be deduced from the 
HPLC chromatogram.   
 
Protein purification by FPLC system 
Ni Sepharose 6 Fast Flow (NiFF) chromatography 
For a 4-liter culture, the cell pellet is resuspended in 75 ml buffer containing 25 mM 
Tris, pH 7.5, 500 mM NaCl, and 30 mM imidazole (NiFF buffer A).  The volumn of the cell 
suspension should be around 90 ml.  The cells are lysed by sonication in two 50ml centrifuge 
tubes for 3 × 1 min (Duty cycle 50, Output Control 7), followed by centrifugation at 14,000 
rpm for 30 min.  The resulting supernatant is incubated with ATP to release the GroEL 
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chaperone protein.  For the ATP wash, 20 ml 100mM stock ATP (in 20 mM Tris, pH 7.5) 
and 4 ml of 1M MgCl2 are added to the supernatant (~80 ml), bringing the final ATP and 
MgCl2 concentration to 20 mM and 40 mM, respectively.  The mixture is incubated with 
gentle stirring at RT for 2 hr. After ATP wash, the cell lysate is filtered throught a 1.2 um 
membrane before loading onto pre-equilibrated NiFF column (7 ml column) with a flow rate 
of  3 ml /min.  The loaded column is washed with 10-12 column volumn (CV) of NiFF buffer 
A. The bound protein is eluted with NiFF buffer B (300 mM Imidazole, 500 mM NaCl, 25 
mM Tris, pH7.5) in a 12CV gradient and 50 ml gradient delay.   
 
MBP affinity chromatography 
For a 1-liter culture, the cells are pelleted and resuspended in 30 ml amylose column 
buffer containing 20 mM Tris, pH 8.0, 200 mM NaCl, and 1 mM EDTA.  Cells are then 
disrupted by sonication (output 7, duty cycle 50, 30 seconds for 3 × 1min) in a 50 ml 
centrifuge tube and spun down at 14,000 rpm for 30 min.  The supernatant is diluted to 50 ml 
with column buffer and applied to 20 ml amylose column column (NEB) at a flow rate 2 
ml/min, then washed with 10 column buffer. The column is eluted by the column buffer 
supplemented with 10mM maltose, and all bound MBP-fusion proteins should be eluted in 
20-25 ml elution buffer.   
 
HiLoad Superdex 75/200 gel filtration chromatography  
The desired fractions of eluent from the NiFF column are combined and the 
concentration is measured by using UV detection at 280 nm.  A 40 mM stock PAP was added 
into the eluent (if the target protein is sulfotransferase) to make the final PAP molar 
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concentration 5 times higher than the protein concentration.  The eluent is then concentrated 
to around 3ml (protein concentration preferably lower than 10 mg/ml) using Amicon 
concentrator.  The concentrated sample is injected into a 10 ml sample loop, then loaded onto 
a pre-equilibrated HiLoad Superdex75 (or Superdex200 for purification of larger proteins) 
column. The column is washed with 20 mM Tris (MOPS), 400 mM NaCl, pH7 at 1 ml/min, 
and the fractions are collected at 2 ml/fraction. The earlier peak (if exist) right after the void 
volumn is usually GroEL chaperone complex, and the target protein peak is normally well 
separated from the early peak (if the target protein is monomeric).  The target protein is 
generally eluted within a volumn of 10-14 ml.   
 
Remove (his)6 or Trx tag by protease digestion 
For His tagged protein, the His tag can be removed by thrombin digestion (if 
applicable, not all expression vectors provide a thrombin digestion site). Generally, the 
digestion is done after the gel filtration chromatography, and the target protein is in 20 mM 
MOPS, 400 mM NaCl, pH 7.  The concentration of the target protein is measured, and then 
thrombin (1 NIH unit/µl) is added to the protein solution at a ratio of 1 unit of thrombin to 
200 µg target protein.  It is strongly advisable that PAP is added into the digestion mixture at 
5 times molar concentration excess of the target protein, if the target protein is a 
sulfotransferase. The protease digestion is then conducted at room temperature (RT), 20-30 
hours is usually enough to achieve 95% of digestion. Please note that RT digestion is not 
recommended for all proteins, one must ensure the target protein is stable at RT by activity 
assay.  Alternatively, the digestion can be done in the cold room (4-10 °C), but the digestion 
period will be at least two times longer to achieve 95% of digestion.  During digestion, 
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rotating the digestion mixture is not necessary (at least for 3OST5 and 2OST), and this 
sometimes will cause massive protein precipitation.  
To analyze if the protease digestion is complete, one can run an SDP-PAGE to 
examine the target protein band shift after digestion. Even though the His tag (and some 
associated sequence) is a very small fragment, removal of the tag will cause a noticeable 
band shift.  The digested sample is then passed through a 400 µl NiFF column to remove His 
tag and remaining undigested His tag protein.  Collect the flow through, which contains the 
majority of the digested target protein.  Then wash the column with 4 ml gel filteration 
column buffer to wash out the residual digested protein on the column.  The flow through 
fraction and wash fraction is then combined and dialyzed against the crystallization buffer.  
For thioredoxin (Trx) tagged protein, the Trx tag can be removed by thrombin or 
tobacco etch virus (TEV) protease digestion, depending on the vector used.  Generally, 
removing Trx tag is conducted before the gel filtration column.  In the case of thrombin 
digestion, the procedure is exactly same as the described above for His tagged protein.  In the 
case of digestion with TEV protease, the protein sample, this time in the NiFF column buffer 
B, is diluted two times in order to reduce the NaCl concentration to 250 mM, because high 
salt concentration will decrease the digestion efficiency of TEV protease.  TEV protease is 
prepared in the lab and stored at -20°C or -80°C in 50% glycerol at a concentration of 0.5 
mg/ml.  Add TEV into the diluted protein sample at a mass ratio of 1 µg of TEV to 100 µg of 
target protein.  Again, adding PAP is advisable if dealing with sulfotransferases. Achieving 
95% of digestion normally requires 30-40 hours at RT.  The completion of the digestion 
reaction can be checked either by SDS-PAGE or gel filtration column using HPLC.  Next, 
the digested sample is concentrated and applied onto HiLoad Superdex 200 (or 75) following 
      59
the FPLC gel filtration column protocol.  The digested target protein peak should be well 
separated from the Trx peak (14-18 kDa), and the target protein fraction are combined and 
dialyzed against the crystallization buffer.     
 
Preparation of crystallization sample 
Dialysis of the crystallization sample directly into the crystallization buffer is 
generally preferred.  PAP is added into the sample to ten times molar concentration excess of 
the target protein, if subject is a sulfotransferase.  For crystallization samples that requiring a 
reducing agent, TECP (Tris(2-carboxyethyl)phosphine hydrochloride) is added to the sample 
at two times molar concentration excess relative to the protein to achieve efficient reducing 
efficacy.  The sample is allowed to react with the TECP for an hour before concentrating.  A 
15 ml Amicon concentrator is used to concentrate crystallization sample.  The sample is 
concentrated to about 1mg/ml, then PAP is added to the final concentration of 1mM.  Then 
the sample is concentrated sequentially to 2 mg/ml, 4 mg/ml, 8 mg/ml (based on sample 
volume reduction) until the desired final concentration is achieved.  At least 2 µl of sample is 
taken at each concentration point for SDS-PAGE analysis, and the protein solution is always 
resuspended with a pipet tip before taking samples.  The final concentration of the 
crystallization sample is estimated by running SDS-PAGE for the samples taken from each 
concentration step including the starting protein sample.  
 
Site-directed mutagenesis 
Design of mutagenesis primers 
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The mutagenesis forward and reverse primers with overlapped mutation site are 
prepared as illustrated in figure 12.  
 
 
 
Figure 12. The guidelines for designing site directed mutagenesis primers. The mutation site (the 
mutation content can be up to 17% of the total primer length) can also be insertion or deletion. Based 
on (146). 
 
PCR reaction is conducted by mixing the following components: 10 x PCR buffer, 5 
µl; 10mM dNTP, 1 µl; template (50-100 ng), 0.5 µl; Pfu polymerase, 1 µl; forward and 
reverse primers (20 uM), 1.5 µl each; H2O, 39.5 µl.  The PCR cycle is as following:  94 °C 
for 3 mins;  94 °C for 1 min, 52 °C for 1 min, 68 °C for 1 min/kb template, repeat for 16 
cycles; 68 °C for 1 hr.  The PCR products are examined by agarose gel electrophoresis, and 
should be farily easy to identify. Then 20 µl PCR product is digested with 1 µl of Dpn I 
(NEB) at 37 °C for 1 hr.  1-2 µl of Dpn I treated PCR product is used to transform 50 µl XL-
10 Gold compenent cells.  
 
Small scale purification of the mutants 
Culture is prepared following the standard protocol for CHAPOrigami-B cells. For 100 
ml culture, cells were pelleted and resuspended in 8 ml NiFF buffer A.  Cells are disrupted 
by sonication (output 4, duty cycle 50, 30 sec for 2 times) in a small bottle, then spun down 
at 14,000 rpm for 20 min. The supernatant is then applied to a 200 µl NiFF gravity column 
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that is pre-equilibrate with 3 ml NiFF buffer A.  The supernatant is filtered through a 0.45 um 
syringe filter and loaded onto the column.  After the unbound protein runs through, the 
column is washed with 3-4 ml NiFF buffer A.  The bound protein is eluted with 1ml NiFF 
buffer B.  
For 500 ml to 1 liter culture, cells were pelleted and resuspended in a similar manner,  
and disrupted by sonication (output 4, duty cycle 50, 45 seconds for 3 times) then spun down 
at 14,000 rpm for 30 mins. The supernatant is then applied to a 1 ml NiFF (Amersham) 
column connected with a FPLC system at a flow rate of 1 ml/min. The purified proteins are 
eluted from the column with a linear gradient of imidazole from 30 mM to 300 mM in 15 ml, 
with a 30 ml gradient delay.   
 
ITC analysis of HS-2OST mutants 
ITC (Isothermal Titration Calorimetry) was performed on a MicroCal VP-ITC.  
Solutions were cooled to 20 °C and degassed under vacuum before use.  Experiments were 
conducted using 20-30 µM protein in 100 mM phosphate buffer, pH 7.0, 300 mM NaCl, 100 
mM arginine and 100 mM glutamate at 20 °C.  Titrations were performed by injecting 5 µl of 
0.7 mM PAP (Sigma) in the same buffer.  Data analysis was completed using Origin 
software. 
 
PAP chromatography analysis of CS-2OST mutant 
PAP-agarose affinity chromatography was used to determine the binding affinity of 
the wild type and mutant proteins of CS-2OST to PAP using an AKTA-FPLC system 
(Amersham).  Approximately 300 µg of proteins in 5 ml of a buffer containing 20 mM Tris, 
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pH 8.2, and 100 mM NaCl (buffer A) was loaded onto a PAP-Agarose column (7 × 52 mm) 
pre-equilibrated with buffer A at a flow rate of 0.5 ml/min. Unbound material was removed 
by washing with 8 ml buffer A.  Bound proteins were eluted with a linear gradient of NaCl 
from 0.1 to 1.5 M in 15 ml, and the eluent was monitored by UV280 nm.  The NaCl 
concentration at the central position of the eluted CS-2OST peak was recorded as the elution 
concentration. 
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Chapter III. Characterization of HS 3OST6 
 
Five different isoforms of 3OST have been identified (3OST1, 2, 3, 4, 5)(11,80). 
These isoforms share greater than 60% homology in the sulfotransferase domain and exhibit 
distinct tissue expression patterns (147,148).  In addition, the isoforms recognize the unique 
saccharide sequences around the modification site(147).    The resultant 3-O-sulfated HS 
generated by different isoforms display distinct biological functions.  For instance, the HS 
modified by 3OST1 and by 3OST5 contain anticoagulant activity, whereas the HS modified 
by 3OST3 and 3OST5 serve as entry receptors for herpes simplex virus 1 (HSV-1) 
(11,62,136,145). 
Screening the nonredundant database of National Center for Biotechnology 
Information with the deduced amino acid sequence of human 3OST3 (accession number 
NM_006042), a mouse homolog was identified from an EST cDNA clone with the accession 
number AI447860 and found to contain a complete open reading frame encoding for a novel 
HS 3OST with 342 amino acid residues.   This protein was designated as mouse 3OST6 
(m3OST6).   In this study, we sought to understand the substrate specificity and potential 
biological function of m3OST6.  The substrate specificity of m3OST6 was determined by 
using the HS isolated from stably transfected 3OST6/CHO cells, which is similar to the 
substrate specificity of 3OST3 in the disaccharide level. Furthermore, we showed that 
3OST6/CHO cells were susceptible to the infection by HSV-1 but not other 
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alphaherpesviruses examined, suggesting that 3OST6 produces a specific entry receptor for 
HSV-1.   Our results indicate that a new member of the 3OST family generates an entry 
receptor for HSV-1.  The finding adds to the growing body of evidence that HSV-1 entry is  
mediated by 3-O-sulfated HS generated by multiple members of 3-O-sulfotransferases.  
 
Substrate Specificity of 3OST6 
Because 3OST6 has high identity with 3OST1, 3OST3 and 3OST5 (Fig. 13), we 
decided to examine its ability to generate 3-O-sulfated HS in transfected cells. Initially, we 
transiently expressed 3OST6 (pcDNA3-3OST-6) in COS-7 cells, however, we failed to 
detect any 3-OST activity in the transfected cells using an in vitro assay (results not shown). 
To overcome this problem, a CHO cell line with stable expression of 3OST6 (3OST6/CHO 
 
 
Figure 13.  Multiple amino acid sequence alignment of human mouse 3OST6 with mouse 3OST1, 
3OST3A, 3OST5.  The alignment was performed by using the program BioEdit.  Introduced gaps are 
shown as hyphens, and aligned amino acids are boxed and shaded with black for identical residues and 
dark gray for similar residues. 5′-PBS represents the putative domain that binds to 5′-phosphate of 
PAPS, and 3′-PBS represents the putative domain that binds to 3′-phosphate of PAPS. 
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cells) was prepared, where a Myc-tag was introduced to the C-terminus of the protein for 
monitoring the level of expression of 3OST6. 
Western blot analysis using anti-Myc antibody was performed on the lysates obtained 
from 3OST6/CHO cells and nontransfected CHO cells (CHO-K1 cells, as a negative control) 
(Fig. 14). We observed two protein bands in the lysate of CHO/3OST6 cells at the molecular 
masses of 38 and 41 kDa (Fig.14), whereas no signals were detected in the non-transfected 
CHO cells. The protein band with lower molecular mass was very close to the predicted 
molecular mass (37.4 kDa) of 3OST6. The protein band with higher molecular mass 
probably represented the 3OST6 with glycosylation or other post-translational modifications. 
 
                                                    
 
Figure 14.   Western blotting analysis of 3OST6/CHO cell extract.  3OST6/CHO and CHO-K1 cell 
extracts were resolved on 13% SDS-PAGE.  Myc tagged 3OST6 was detected by incubating blot with 
mouse anti-myc antibody and then horseradish peroxidase conjugated anti-mouse IgG secondary 
antibody.  The apparent molecular weights of the two bands were around 38 kDa and 41 kDa.  The 
predicted MW of 3OST6-Myc/His is  37.4 kDa.  
 
To characterize substrate specificity of 3OST6, we analysed the structure of the HS 
isolated from 3OST6/CHO cells by conducting the disaccharide analysis. The 3OST6/CHO 
cells were metabolically labeled with Na235SO4, and the [35S]HS was isolated. The resultant 
[35S]HS was subjected to nitrous acid degradation at pH 1.5, followed by sodium 
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borohydride reduction to prepare 35S-labeled disaccharides (the schematic representation of 
the disaccharide analysis of [35S]HS illustrated in Fig. 15C). The 35S-labeled disaccharides 
were resolved by RPIP-HPLC, and the chromatograms are shown in Figure 15. Comparing 
the profiles of the degraded [35S]HS that was isolated from CHO-K1 cells (Fig. 15A), we 
found two additional 35S-labelled disaccharides in the HS from 3OST6/CHO cells (Fig. 15B). 
Those two 35S-labelled disaccharides were 3-O-sulfated disaccharides with the structures of 
IdoUA2S-AnMan3S (eluted at 36.5 min) and IdoUA2S-AnMan3S6S (eluted at 69.5 min) by 
co-eluting with the disaccharide standards (10). A large peak of 35S-labelled disaccharide 
with a structure of IdoUA2S-AnMan6S (AnMan6S is 2,5-anhydromannitol 6-O-sulfoate) 
was also observed (eluted at 56–58 min) both in the samples from CHO-K1 and 3OST6/CHO. 
The presence of 35S-labelled IdoUA2S-AnMan6S is expected because it is a common 
disaccharide in HS. We should also observe IdoUA-AnMan6S after nitrous acid (pH 1.5) 
degradation of [35S]HS, which is a monosulfated disaccharide from nitrous acid degraded 
polysaccharide. To identify this monosulfated disaccharide requires a different HPLC 
condition. The HPLC condition used in the present study is designed to identify both 
disulfated and trisulfated disaccharides (10). This condition provides the best resolution 
among disulfated and trisulfated disaccharides. However, it does not provide the best 
resolution for monosulfated disaccharides. These results suggest that the HS isolated from 
3OST6/CHO cells contain 3-O-sulfated HS, therefore 3OST6 encodes a protein with the 
anticipated 3-OST activity. Unlike previously reported 3-OST isoforms, we were unable to 
detect the 3-OST activity in the lysate of 3OST6/CHO cells by an in vitro assay, suggesting a 
unique biochemical property of 3OST6.  In a parallel control experiment, we readily 
observed the activity of 3OST5 in the extract of 3OST5/CHO cells by using this in vitro 
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assay (results not shown). It is important to note that IdoUA2S-AnMan3S and IdoUA2S-
AnMan3S6S are characteristic gD-binding HS disaccharides (62).  
 
 
Figure 15.  RPIP-HPLC chromatograms of the disaccharide analysis of HS isolated from 
3OST6/CHO.  [35S]HS was extracted from CHO-K1 (A) and 3OST6/CHO (B) cells after incubating 
them with [35S]Na2SO4.  [
35S]HS was then depolymerized by nitrous acid at pH 1.5 followed by 
sodium borohydride reduction.  The resultant 35S-labelled disaccharides were resolved on RPIP-
HPLC.  The elution positions of disaccharides are indicated by arrows, where arrow 1 represents 
IdoUA2S-AnMan3S; arrow 2 represents IdoUA2S-AnMan6S; arrow 3 represents IdoUA2S-
AnMan3S6S.  (C) Illustrates the reaction used for degrading HS with nitrous acid.  Nitrous acid (at pH 
1.5) reacts with N-sulphated glucosamine unit to form 2,5-anhydromannitol (AnMan).  The identities 
of the resultant disaccharides were determined by coeluting with disaccharide standards on RPIP-HPLC 
 
The binding of the HS from 3OST6/CHO to AT was also determined to evaluate the 
substrate specificity of 3OST6, as the saccharide sequences for binding to gD (serving as 
HSV-1 entry receptor) and AT (having anticoagulant property) are distinct. The results from 
this experiment allowed us to identify whether 3OST6 is more similar to 3OST3 or to 3OST5. 
We observed only 0.8% of 3OST6/CHO HS bound to AT, which is very close to that of the 
HS isolated from non-transfected CHO cells (0.5%) (Table 1). In contrast, the binding of 
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3OST5/CHO HS to AT was 7.6-fold higher than the that of the HS from non-transfected 
CHO cells control sample, which is consistent with the conclusion that 3OST5 generates AT-
binding sites (11). The results from AT-binding assay suggest that 3OST6 does not generate 
AT-binding sites. Therefore the substrate specificity of 3OST6 and 3OST5 is distinct. 
              
 
              TABLE I   
             The binding of 3OST6/CHO HS to gD and AT 
 
Binding of the HS and gD was determined by incubating modified [35S]HS with gD 
followed by immunoprecipitation using anti-gD monoclonal antibody (DL6) to 
precipitate the complex of [35S]HS and gD.  Data are presented as the mean ±S.D., 
where n represents the number of determinations. The binding of the HS to AT was 
determined by incubating modified [35S]HS and AT followed by affinity precipitation 
with AT/ConA-Sepharose beads. Control was the [35S]HS extracted from CHO-K1 
cells labelled with [35S]Na2SO4. 
 
                                                      
 
 
3OST6 Modified HS Serving as HSV-1 Entry Receptor 
Non-transfected CHO cells are resistant to HSV-1 infection. However, introduction of 
the cDNA that allows the cells to synthesize an entry receptor renders the susceptibility of 
CHO cells to HSV-1 infection. A significant increase in β -galactosidase activity was 
observed in 3OST6/CHO cells infected by HSV-1, compared with that of CHO-K1 cells (Fig. 
16A). Furthermore, the level of β-galactosidase was comparable with the HSV-1-infected 
cells that stably express 3OST5 (3OST5/CHO) (Fig. 16A). 3OST5 is known to generate an 
entry receptor for HSV-1 (11). We also compared the activity of β-galactosidase in situ. As 
expected, nearly all of 3OST6/CHO cells were susceptible (Fig. 16B, dark cells) to the entry 
 Binding to gD (%) Binding to AT (%) 
Control 3.8 ± 0.9 (n = 2) 0.5 ± 0.1 (n = 3) 
HS from 3OST6/CHO 8.8 ± 2.0 (n = 2) 0.8 ± 0.2 (n = 3) 
HS from 3OST5/CHO 7.3 (n = 1) 4.1 ± 1.2 (n = 3) 
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of HSV-1. Clearly, no dark cells were observed in CHO-K1 cells infected with the same 
HSV-1 (Fig. 16C). Our results suggest that 3OST6 renders the susceptibility of CHO cells to 
HSV-1 infection. A direct binding between 3OST6-modified HS to gD was also detected 
(Table 1). As expected, the HS from 3OST6/CHO cells has an approximatly 2.3-fold increase 
in binding to gD as compared with the HS from CHO-K1; a similar increase was observed 
for the HS from 3OST5/CHO cells. Taken together, these observations are consistent with 
the conclusion that 3OST6 generates HSV-1 entry receptor and that the entry mediating 
activity of 3OST6 is very similar to that of 3OST5.  
                      
Figure 16. Entry of HSV-1 into 3OST6/CHO cells and CHO-K1 cells.  (A). As indicated 
3OST6/CHO, 3OST5/CHO and CHO-K1 cells were infected with several PFUs/well of HSV-
1(KOS-gL86).  The cells were lysed for quantification of β-galactosidase activity as a measure of 
viral entry.  Optical densities at 410 nm (OD410) of ONPG reaction products were plotted against 
PFUs used.  3OST6/CHO (B) and CHO-K1 cells (C) were exposed to KOS-gL86 at 100 plaque-
forming units (PFUs)/cell.  Six hours later, the cells were washed, fixed and incubated with X-gal to 
identify infected cells (dark blue cells).   
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In separate experiments, we also examined the activity of 3OST6 in assisting the 
entry of other members of alphaherpesvirus subfamily, including HSV-2, PRV and BHV-1. 
We found that, very much in line with previously characterized 3-O-sulfatedHS generated by 
3OST3 and 3OST5 (11,62), the cells expressing 3OST6 are resistant to the infection by these 
other members of the alphaherpesvirus subfamily (results not shown).  
To strengthen further the conclusion that 3OST6-modified HS provides an entry 
receptor for HSV-1, we examined whether 3OST6-expressing cells (target cells) could 
induce fusion with the cells expressing HSV-1 envelope proteins essential for viral fusion 
(effector cells). This cell–cell fusion assay mimics the fusion of HSV-1 to the target cells, 
and the fused cells are readily quantified with an appropriate reporter gene and visualized 
under a microscope. In the assay, the target cells also carried an inducible luciferase as a 
reporter gene that is activated upon the fusion with effector cells to permit quantification of 
the cell–cell fusion (136,149). As shown in Figure 17A, we found that CHO cells transiently 
transfected with 3OST6 efficiently fused with the effector cells expressing gB, gD, gH and 
gL, as determined by the elevated level of luciferase. Fusion between cells was very similar 
to that observed with similarly transfected 3OST5 cells, which served as a positive control 
for the fusion experiment (150). The cell–cell fusion mediated by 3OST6 was also visualized. 
Cells expressing 3OST6 resulted in polykaryocyte formation, an indication of cell–cell fusion 
(Fig. 17C), whereas no polykaryocytes were observed using CHO-K1 as target cells (Fig. 
17B). These data also suggest that 3-O-sulfated HS can potentially mediate viral spread 
among neighboring cells.  
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Figure 17.  Cell-cell fusion mediated by 3-O-sulphated HS.  (A) Cell fusion is dependent on 
expression of 3OST6.  CHO-K1 cells were used as effector and target cell.  Effector cells were 
transfected with plasmid expressing HSV-1 glycoproteins and luciferase reporter plasmids.  Target 
cells were transfected with T7 RNA polymerase and the plasmid expressing 3OST5 or 3OST6.  
Luciferase activity was measured 24 h after mixing and cocultivating the effector and target cells.  
The luciferase activity is from one experiment performed in triplicate.  (B) and (C) are the 
microscopic images for the observation of HSV-1 glycoprotein induced-cell fusion. CHO-K1 
effector cells were transfected with HSV-1 glycoproteins (gB, gD, gH and gL).  The target CHO-
K1cells were either transfected with an empty vector (B) or with the plasmid expressing 3OST6 (C).  
Cells were fixed and then stained with Giemsa.  Shown are the photographs of representative cell 
monolayers taken after 24 h.  Arrows (in Panel C) indicate the polykaryocyte cells. 
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Conclusion 
HSV-1 utilizes distinct families of cell-surface molecules as entry receptors for 
infection via an unknown mechanism (151). One of the families is 3-O-sulfated HS, which 
interacts with gD with a binding affinity in the micromolar range (130) The 3-O-sulfated HS 
is biosynthesized by specific 3-OSTs. In the present study, we report the isolation and 
characterization of a novel 3-OST cDNA, namely 3OST6. To our knowledge, the 
biochemical functions and enzymatic activity of this gene have not been reported. The cDNA 
was identified by homology sulfotransferase that synthesizes an entry receptor for HSV-
1(62). We utilized a similar approach to successfully identify 3OST5 (11). Our results 
demonstrated that 3OST6 cDNA encodes a protein that has 3-OST activity, and synthesizes 
an entry and cell–cell fusion receptor for HSV-1, but not for other subtypes of the 
alphaherpesvirus family. The isolated cDNA encodes a type II membrane-bound protein, 
which is consistent with the structural features found in all previously characterized 3-OST 
isoforms, including 3OST1 [a secreted enzyme, containing a signal peptide (12-amino-acids 
long)], 3OST2, 3OST3 and 3OST5(11,80).  The full-length cDNA sequence for 3OST4 has 
not been published.  As expected, the HS isolated from 3OST6/CHO cells binds to gD and 
contains two characteristic 3-O-sulfated disaccharides (IdoUA2S-AnMan3S and IdoUA2S-
AnMan3S6S), suggesting that 3OST6 sulfates similar disaccharides to those sulfated by 
3OST3. It should be noted, however, that we do not know whether the saccharide sequences 
of the gD-binding sites in 3OST3-modified HS and those in 3OST6-modified HS are 
identical. We also identified the human 3OST6 from a genomic clone with accession number 
AE006640.1, because the gene encodes a protein having 94% sequence identity with mouse 
3OST6. 
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One of the reasons for successfully characterizing the sulfotransferase activity of 
3OST6 was that we obtained a CHO cell clone that stably expresses 3OST6 gene. It is very 
interesting to note that we were unable to detect the activity of 3OST6 in the cellular extract 
using an in vitro assay, which has been successfully used to characterize all previously 
reported 3-OSTs (11,89,90). This observation suggests two possible explanations: either 
3OST6 activity is unstable under in vitro experimental condition, or the enzyme sulfates a 
very unique HS substrate that is absent in the HS utilized for the in vitro assay. (HSs from 
three different sources, including the HS from bovine kidney, from non-transfected CHO 
cells and from mouse L-cells, were examined. None of these HSs is a substrate of 3OST6.) 
The physiological functions of 3-O-sulfated HS, generated by 3OST3, 3OST2 and 3OST6, 
are not known despite the fact that it serves as an entry receptor for HSV-1.  It is known that 
the 3-O-sulfated HS biosynthesized by 3OST1 serves as an anticoagulant on the surface of 
endothelial cells, although 3OST1-modified HS is not an entry receptor for HSV-1 
(62,152,153).  The 3-O-sulfated HS biosynthesized by 3OST5 display the activities in 
anticoagulation and in assisting HSV-1 entry (11).  Reports suggest that 3-O-sulfated HS 
could be involved in numerous biological functions, and 3-OST genes are present among the 
animal kingdoms from Caenorhabditis elegans and Drosophila to humans (147,150).  Edge 
and Spiro (154) reported that decreased levels of IdoUA-AnMan3S and IdoUA2S-AnMan3S 
in HS isolated from the glomerular basement membrane were observed in diabetic patients. 
Since IdoUA2S-AnMan3S is the product of 3OST3, 3OST2, 3OST6 or 3OST5, and IdoUA-
AnMan3S is the product of 3OST5, these results suggest that the specific 3-Osulfated HS 
might contribute to defects in the anionic filtration barrier in diabetic patients. The expression 
of 3OST2 in rat pineal gland is daylight-sensitive and is regulated by the β-adrenergic 
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signaling pathway (87). In addition, a lower expression of 3OST2 was discovered in various 
human cancers, suggesting potential roles of 3OST2 in controlling the transformation of 
normal cells to cancer cells (86). 
The wide host range of HSV infection is possibly because of the ability of the virus to 
use multiple cell-surface molecules, including 3-O-sulfated HS, for entry (155).  The 
discovery of 3OST6 as an enzyme for the biosynthesis of a gD receptor adds to the growing 
body of evidence that several members of 3-OST family generate such receptors.  
Collectively, these members are expressed in a wide variety of human cell types and tissues 
(Table 2) (A northern blotting analysis of the tissue distribution of 3OST6 is shown in figure 
18).  Thus wide expression of the enzymes raises the possibility that 3-O-sulfated HS is 
present in many cell types, and could potentially play a significant role in HSV-1 entry and 
spreading during primary or disseminated diseases. The disseminated form usually involves 
the liver, adrenal gland and lung. It is very interesting that 3OST6, along with 3OST3, is 
expressed in the liver. We reported recently that co-expression of 3-OST isoforms can 
actually enhance HSV-1 entry and cell fusion, potentially by enhancing the gD-binding sites 
within HS chains (136). It raises the possibility that co-expression of 3OST6 and 3OST3 
could also enhance the susceptibility of liver cells forHSV-1. This possibility would require 
further experiments to confirm. 
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Figure 18.  Expression of 3OST6 mRNA in mouse tissues. A mouse multiple tissue Northern blot was 
hybridized with mouse 3OST6 cDNA probes labelled with [32P]dCTP under the conditions described 
in chapter II.  3OST6 was expressed primarily in liver with sizes of ~1.6 kb and ~3.6 kb and in kidney 
with a size of ~1.6 kb, and also expressed at lower level in heart, brain, lung and testis.  
 
 
TABLE II 
Tissue distributions of 3-O-sulfotransferase isoforms and the biological functions of  
3-O-sulfated HS 
 
a. Tissue distributions of human 3OST1, -2, -3A, -3B, and –4 were reported by 
Shworak  et al(147).  Tissue distribution of human 3OST5 was reported by Xia et al. 
and Mochizuki et al.(11,148).   
b. 3OST3A and 3OST3B have identical amino acid sequence in the sulfotransferase 
domain.  
 
3-OSTs Isoforms   Tissue Distributiona Known Properties 
     3OST1   Heart, Brain, Lung, Kidney Anticoagulant HS 
     3OST2   Brain HSV-1 entry 
     3OST3Ab   Heart, Placenta, Lung, Liver, Kidney HSV-1 entry 
     3OST3Bb  Heart, Brain, Lung, Liver, Kidney HSV-1 entry 
     3OST4  Brain HSV-1 entry 
     3OST5  Brain, Spinal cord, Skeletal muscle  Anticoagulant HS  
HSV-1 entry 
     3OST6  Liver, Kidney HSV-1 entry 
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Similarly, the inability of 3-O-sulfated HS to mediate HSV-2 entry raises the 
possibility of mechanistic differences between the entry of HSV-1 and -2, where HSV-2 
infections commonly occur in genital tissues.  The differences could be at the level of 
receptor recognition or at a subsequent step during the entry. In either case, our observation 
suggests that receptors could play a role in deciding the tissue tropism.  More conclusive 
studies on the cellular expression of 3-OSTs and their significance in cell types that are 
natural hosts to HSV-1 are needed to test this possibility.  Such studies will be beneficial not 
only for understanding the pathogenic effects of the virus, but also to dissect it from HSV-2 
pathogenesis. 
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Chapter IV. Expression and Crystallization of HS 3OST5 
and HS 2OST 
 
 
Continuing on our productive research on the structure-function relationship of 
3OSTs, we sought to determine the crystal structure of 3OST5 in complex with different 
saccharide substrates.  From the structural study of 3OST5, we expect to advance our 
understanding of the molecular recognition mechanism between 3OSTs and distinct 
saccharide sequences.  Understanding the mechanism of action of 3OSTs will aid in 
discovery of inhibitors for 3OSTs.  Specific 3OST inhibitors will be valuable for 
investigating the relationship between the saccharide structures and their biological functions.  
Additionally, the same structural information will assist us in designing 3OST variants with 
alternate substrate specificities by introducing appropriate mutations.  
In addition, we plan to study the structural features of an essential HS biosynthetic 
enzyme: 2OST.  2-O-sulfation has been determined to be a crucial modification of HS that is 
involved extensively in the signaling transduction pathways of many essential developmental 
processes.  However, the structural study of 2OST has been lacking, which greatly impeded 
out understanding of the detailed substrate recognition mechanism, catalytic mechanism and 
the role of its interactions with C5-epi in regulating the fine structures of HS.  We expect the 
crystal structure determination for 2OST will greatly advance our knowledge in all these 
respects.  
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Chaperonine Assisted Expression of 3OST5 in E. coli 
Expression of 3OST5—Achieving a highly efficient expression of 3OST5 is essential 
for the structural studies.  Initially, we wanted to use the same method to express 3OST5 as 
was used to express 3OST1 and 3OST3.  However, we found expressed His3OST5 (3OST5 
with His tag at the N-terminus) formed inclusion bodies and thus was insoluable when 
expressed in BL-21 cells.  We tried to solve this problem first by transforming 3OST5 into 
different E. coli cell lines to test which one gives the best solubility of His3OST5.  Among the 
six cell lines we tested, Origami-B and Rosetta-Origami-B cells (Novagen) gave better 
solubility and activity profiles, but the activity was still low.  One possible reason for the 
decreased activity is that the recombinant protein is folded incorrectly. To overcome this 
problem, we incorporated a novel protein expression technique into our expression system, 
which is the chaperone co-expression technique. Briefly, a separate plasmid containing the 
coding sequences of E. coli chaperonin protein GroEL and GroES was used to transform 
Origami-B cells first to make CHAPOrigami-B competent cells.  Next, 3OST5 expression 
vector was transformed into CHAPOrigami-B cells.  The function of GroEL/ES is aid in the 
folding process of many proteins that have difficulties efficiently folding themselves. As we 
expected, the solubility and activity of His3OST5 increased dramatically after co-expression 
with GroEL/ES.  The anticoagulant activity of His3OST5 modified HS was confirmed by AT 
binding experiment, which is comparable to the activity of the HS modified by insect cells 
expressed 3OST5(152).  The specific activity of His3OST5 was also confirmed by conducting 
a disaccharide analysis of the HS in vitro modified by His3OST5(11,152), observing the 
presence of 3-O-sulfated disaccharides (disaccharides 1, 2, 3, 4; figure 19).  
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Purification of 3OST5—A common problem with the chaperone co-expression 
system is that GroEL may form a tight complex with the target protein and cause difficulties 
for purification (156). We attempted to use two methods to get around this problem.  First, 
because the dissociation of folded native protein from GroEL/ES depends on hydrolysis of 
ATP (157), the cell lysate was incubated with ATP for several hours to accelerate this 
dissociation process.  ATP-treated cell lysate was then subject to NiFF affinity 
chromatography.  However, we found that the NiFF column was not sufficient to get rid of 
all GroEL; a noticeable amount of GroEL co-eluted with His3OST5.  Based on the 
assumption that only a small portion of  His3OST5 still forms a complex with GroEL after 
NiFF chromatography, we determined if gel filtration chromatography would separate free 
His3OST5 (32 kDa) from GroEL/His3OST5 complex (400-800 KDa) since they have 
significant differences in mass.  Our results showed that gel filtration chromatography was 
adequate for separating these two populations and gave us pure His3OST5 as shown in figure 
20.   
              
 
Figure 19. RPIP-HPLC chromatograms of the disaccharide analysis of His3OST5 modified HS. 
In vitro modified [35S]HS were treated with nitrous acid (pH 1.5) followed by sodium 
borohydride reduction. The disaccharides were desalted and resolved by RPIP-HPLC. The 
elution positions of disaccharide standards are indicated by arrow 1: IdoUA2S-
AnMan3S,arrow 2: IdoUA-AnMan3S6S, arrow 3: GlcUA-AnMan3S6S, arrow 4:IdoUA2S-
AnMan3S6S.  Among them, GlcUA-AnMan3S6S is the essential disaccharide unit presented 
in aHS.   
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However, when we started preparing large quantity of His3OST5, we got a very low 
yield using this two-step of purification due to severe His3OST5 precipitation.  The 
precipitation occurred during concentration of eluent from the nickel column, which is a 
necessary step for applying the sample onto gel filtration column.  The highest concentration 
His3OST5 remains soluable was approximately 1 mg/ml, which would make crystallization 
process very difficult or impossible.  
                                         
 
 
Figure 20. PAGE analysis of purified 3OST5. The analysis was carried out on 15% SDS-PAGE, 
the gel was stained by coomassie blue.  Lane 1, purified protein after NiFF column; lane 2, 
purified His3OST5 after gel filtration column.  
 
Increasing the Solubility of 3OST5 Through Targeted Mutations 
Preparation of 3OST5 mutants with higher solubility—The extremely low solubility 
of 3OST5 is surprising because the solubility of 3OST1 and 3OST3 are easily above 10 
mg/ml, and those three enzymes share 60-70% homology of amino acid sequences.  In order 
to determine possible regions that confer the low solubility of 3OST5, we reasoned that we 
must closely examine at the regions that are dissimilar among those three isoforms.  
Numerous studies indicate that long stretch of hydrophobic residues at the surface without 
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the interruption of charged residues could contribute to the low solubility of a protein 
(158,159).   In addition, if the uninterrupted hydrophobic residue stretch is located within β 
sheets, it may have even higher chance to influence the protein solubility.   With above 
mentioned concepts in mind, we located a highly hydrophobic region in 3OST5, from residue 
F297 to N302, which differes from corresponding regions of both 3OST1 and 3OST3 (Fig. 
21A).  This region of 3OST5 contains four highly hydrophobic residues (two isoleucines and 
two phenylalanines), flanked by two Asn residues without the interruption of any charged 
residues.  In contrary, at the corresponding regions of 3OST1 and 3OST3, there is not a 
single bulky hydrophobic residue and have at least two charged residues.  Moreover, 
examining the spatial location of this region by looking at the crystal structural of 3OST1, we 
found that this region protrudes from the globular protein body, giving this region a high 
potential to initiate oligmerization or aggregation (Fig. 21B).  More interestingly, this region 
is located within the connecting loop of 9th and 10th β sheets (based on solved 3OST3 crystal 
structure), and it is flanked by two essential cysteines, which form an important disulfide 
bond.   Combining all these findings, we conducted a site-directed mutagenesis to change the 
nature of this suspicious region, attempting to increase the solubility of 3OST5 to the 
comparable levels of 3OST1 and 3OST3.  
Three groups of mutations have been made to change the hydrophobic nature of the 
region. The first group is composed of single mutations, including I299E, I300E and F301R.  
The second group comprises three double mutations: F297D-I299E, F297D-I300E and 
F297D-F301R.  The third group includes two swap mutations, mutating the whole 
hydorphobic region of 3OST5 to the corresponding region of 3OST1 and 3OST5, 
respectively.  
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The mutants were made using a standard site-directed mutagenesis method and were 
transformed into CHAPOrigami-B competent cells.  All mutants were successfully expressed 
and specific enzymatic activities were measured.   As shown in table III, mutants I299E and 
F301R have enhanced activities comparing to WT His3OST5, while all other mutants have 
decreased or unchanged enzymatic activities. 
 
                  TABLE III.  
Summary of the analysis of the sulfotransferase activity of 3OST5 solubility 
mutants 
 
 
 
The increased enzymatic activities of I299E and F301R may directly relate to their 
improved solubility.  So we compared the ratio of insoluble (inclusion body) fraction and 
soluble fraction of each of these two mutants to that of WT His3OST5.  As shown in figure 22, 
the ratio of insoluble to soluble in WT is 80:20. This ratio was improved to 60:40 in F301R, 
and about 50:50 in I299E.  The difference is even more obvious when comparing the purified 
mutants to WT (elu lanes of figure 22).  These initial findings implied that mutants I299E 
and F301R truely improved the solubility of His3OST5.  Then a thorough solubility test of the 
mutant I299E was conducted by using gel filtration column on HPLC.  As expected, no 
obvious precipitation was observed when the concentration of I299E went as high as 10 
mg/ml, which is a substantial improvement over WT His3OST5’s maximum concentration of 
1 mg/ml.   
Name of constructs Relative activity 
wild type 100% 
I299E 700% 
I300E 40% 
F301R 300% 
F297D I299E 20% 
F297D I300E 40% 
F297D F301R 100% 
3OST1 swap 40% 
3OST3 swap 30% 
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Figure 21. A, Alignment of 3OST5 to 3OST1 and 3OST3A around the hydrophobic region of 
3OST5.  Within the dashed box, acidic residues are shown in red and basic residues are shown in 
blue. B, Comparison of 3OST1 and 3OST5 at the mutated region in 3OST5.  The hydrophobic 
region of 3OST5 is modeled onto the crystal structure of 3OST1 by replacing the corresponding 
residues of 3OST1. The residues within the dashed box in A are shown in spheres, the 
tetrasaccharide substrate is shown in stick and ball (modeled in based on the structure of 3OST3-
PAP-Tetrasaccharide); the PAP is shown with stick in green; and the invariant disulfide bond 
between β9 and β10 is show with stick in orange.  
A
B
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Figure 22.  PAGE analysis of the solubility of 3OST5 WT, I299E and F301R.  ppt, 
precipitant fraction after centrifugation of cell lysate; sol, soluable fraction after 
contrigugation of cell lysate; elu, eluent from Ni fastflow column 
 
 
To make sure the mutant I299E does not change the substrate specificity of 3OST5, 
we performed a disaccharide analysis of I299E modified polysaccharide by using the 
previously described method.  The result was as expected and essentially identical to the 
analysis result of WT 3OST5. 
Crystallization of 3OST5 mutant I299E (3OST5I299E)—From a 6-liter preparation, we 
successfully purified 20 mg of 3OST5I299E after above mentioned two-step chromatography.  
TCEP, a commonly used reducing agent in crystallization set ups, was added into the pooled 
fractions containing pure 3OST5I299E from gel filtration column at a concentration two times 
over that of 3OST5I299E.  PAP was also added into the sample at a concentration five times 
over that of 3OST5I299E.  The sample was then concentrated from 0.5 mg/ml to 8-10 mg/ml 
by centrifuge concentration.  The sample buffer was exchanged with the crystallization 
buffer (20 mM Tris, 200 mM NaCl, 1 mM PAP, pH7.5) while concentrating.  The 
concentrated sample was immediately flash frozen in liquid nitrogen and stored at -80 °C for 
crystallization trials.  
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Crytallization trials were undertaken using the hanging drop method as described (77).  
The crystals of 3OST5 tend to grow very slowly, and it took 8-10 months to get some 
crystals that are large enough to conduct data collection.  One of the 3OST5 crystals diffract 
to a resolution of 2.3 Å.  The overall folding of 3OST5 is extremely similar to that of 3OST1 
and 3OST3, as expected (Fig. 23).  The structure of 3OST5, along with the structures of 
3OST1 and 3OST3, allow us to investigate the critical residues that contribute to the broad 
substrate specificity of 3OST5 by conducting mutational study.  In addition, optimization of 
the 3OST5 crystal conditions is underway in order to gain faster growing, larger crystals, for 
the purpose of co-crystallization or soaking with oligosaccharide substrates.    
          
 
 
Figure 23.  The superimposed structure of 3OST5, 3OST1 and 3OST3.  Stereo diagram of the Cα 
trace of the crystal structures of 3OST5 (green, PAP is also in green) with 3OST1 (blue) (PDB code 
1VKJ) and 3OST3 (gray, tetrasaccharide is in purple) (PDB code 1T8U).  
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Chaperone Assisted Expression of 2OST in E. coli 
Expression and purification of N’-His2OST—The same method of expressing His3OST5 
was applied to the expression of 2OST. Briefly, the entire transmembrane domain along with 
some cytoplasmic regions at the N-terminus of Chinese hamster 2OST is removed in order to 
improve solubility.  pET15b-2OST constructs were transformed into CHAPOrigami-B cells, 
and the enzymatic activities of the resulting N’-His tagged 2OSTs were checked.   The E.coli 
expressed 2OST had very good specific activity.  This 2OST construct, termed N’-His2OST 
hereafter, was then prepared by growing a 12-liter culture.  An ATP incubation step was used 
before applying the lysate onto the nickel column.  Different from the situation for 3OST5, 
approximately 30 mg of N’-His2OST was obtained at high purity using a single-step nickel 
column purification, without significant GroEL contamination.  However, N’-His2OST had 
very poor solubility, and could only be concentrated to 0.5 mg/ml in a buffer containing 20 
mM Tris and 500 mM NaCl.  A novel method was used to improve the poor solubility of N’-
His2OST.  In this method, the sample was dialyzed against 20 mM Tris, 200 mM NaCl and 
100 mM Arg-Glu at pH7.  After dialysis against a buffer containing Arg-Glu, the solubility 
of N’-His2OST was greatly improved and it could be concentrated to 3 mg/ml.  The 
concentrated sample was used for crystallization.  We were able to grow multiple crystals, 
but unfortunately, none of these crystals diffracted very well.   
Expression and purification of 2OSTC’His—Studies have shown that putting a His tag 
on a protein often decreases the protein’s solubility.  In addition, placing a His tag at the N-
terminus versus the C-terminus may have different effects on the solubility of a protein (160).  
In light of this, we cloned 2OST into a different vector pET21b, giving rise to C-terminal His 
tagged 2OST (2OSTC’His hereafter).  Expression and purification procedures were carried out 
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as described for N’-His2OST.  The activity and solubility of the resulting 2OSTC’His were 
compared with that of N’-His2OST, as shown in figure 24.  Amazingly, we found the solubility 
of 2OSTC’His is significantly improved over N’-His2OST.  About 40% of expressed 2OSTC’His 
is in soluble form, comparing to N’-His2OST’s mere 10% soluble fraction.    
In addition, we also investigated the possibility that different N-terminal truncations 
may influence the solubility of the recombinant 2OST.  A total of five N-terminal truncations 
were compared for solubility characteristics.  We observed that the smaller the truncation, the 
better the 2OST solubility (Fig. 25).   From a 100 ml culture, about 30 times more 2OST-1st 
truncation could be obtained than the 2OST-5th truncation, as estimated by their relative 
activities in the NiFF eluent.  The original truncation used was the 2OST-2nd truncation, thus 
by switching to the 2OST-1st truncation, we gained a three fold increase in solubility.  This 
construct, named 2OST-1stC’His, was used thereafter for 2OST crystallization sample 
preparations.  
                                  
 
Figure 24. SDS-PAGE analysis of the solubility of 2OSTC’His and N’-His2OST. The supernatant 
represents the soluble portion of 2OST (sol). The cell pallets were resuspended in equal volumn of 
water as the supernatants, representing precipitated portion of 2OST (ppt). The supernatant were 
loaded onto a 200 µl Ni FastFlow column, and eluted by 1ml in nickel column buffer A (elu). The 
relative ratio of ppt versus sol for each construct in indicated at the bottom.  
 
      88
 
A 2-liter culture of 2OST-1stC’His was prepared,  allowing for a thorough solubility 
test of 2OST-1stC’His.  Approximately 30 mg of pure 2OST-1stC’His was obtained using a 
single step of nickel column chromatography.  Next, the sample was concentrated gradually 
to increasing concentrations and a gel filtration column (HPLC) was used to analyze the 
solubility potential of 2OST-1stC’His.  As shown in figure 25, no precipitation was observed 
when the concentration of 2OST-1stC’His went as high as 6 mg/ml, which is a significant 
improvement over N’-His2OST’s maximum concentration at 0.5 mg/ml.  Two samples were 
prepared for crystallization, one is in a buffer consisting of 20 mM HEPES, 350 mM NaCl, 2 
mM PAP at pH7, and the other is in a buffer consisting of 20 mM MES, 350 mM NaCl, 2 
mM PAP at pH6, both with a concentration of 5 mg/ml.  Multiple crystals were developed 
 
Figure 25. The effect of truncation length on the solubility of 2OSTC’His.  The truncation positions of 
various 2OSTC’His constructs are shown on the amino acid sequence of hamster 2OST.  A 100 ml culture 
of each truncation was prepared and purified by NiFF column. The yields of the truncations are 
compared by SDS-PAGE, and their relative activities are shown in the bottom row.  
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from both samples at varied sizes. The crystals that gave the highest quality diffraction were 
obtained from the pH7 sample, but the highest resolution achieved is approximately 3 Ǻ. 
This resolution does no allow for good determination of side chain conformations.    
We suspect that the major reason that prevents us from getting well-formed crystals is 
the heterogeneity of the 2OST recombinant protein preparation.  As one can observe from 
figure 26, not all 2OST eluted in the monomer form (23 ml) from the gel filtration column.  
Other oligomeric states are also possible as the 2OST peak shows a big shoulder eluting 
ahead of the monomer form.  Indeed, we found that on another gel filtration column (HiLoad 
Superdex 75), the 2OST aggregated badly and no monomeric 2OST could be recovered.  In 
order to solve this problem, we are currently trying different expression methods that favors 
disulfide bond formation (2OST has closely clustered 4 essential cysteines) better than our 
current method.  Moreover, we are also attempting to express 2OSTs from different species, 
as it has been shown the same protein from different species may show very different 
properties in terms of solubility and crystallization.  
 
              
Figure 26. HPLC gel filtration analysis of the solubility of 2OSTC’His.  Black line, 
unconcentrated sample at 0.2 mg/ml; red line, concentrated to 1 mg/ml; green line, 
concentrated to 3 mg/ml; blue line, concentrated to 6mg/ml.  For each concentration, 200 µl of 
2OSTC’His sample was injected.  
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Conclusion 
The first hurdle we encountered during the 3OST5 crystallization project was the 
difficulty to express active 3OST5 in the conventional E. coli expression system.  This 
problem was partly solved by combining a highly soluble protein fusion tag (maltose binding 
protein) and a unique protein expression E. coli strain, Origami-B cell, which is designed to 
favor the disulfide bond formation in the cytoplasm. However, the expressed fusion protein 
had poor purity with a predominant contamination from the chaperone protein GroEL. 
GroEL is an endogenous E. coli protein serving as molecular chaperone that assists the 
folding process for other proteins.  It appears that the folding of 3OST5 depends on GroEL 
since they bind tightly to each other.  In light of this finding, we coexpressed GroEL with 
3OST5, hoping that overexpressed GroEL would help 3OST5 fold more efficiently.  Indeed, 
in the coexpression system, 3OST5 is expressed at higher levels, and with excellent activity.  
The copurified GroEL is then separated from 3OST5 by gel filteration chromatography to 
give pure 3OST5 free from contaminants.  So, a novel protein expression method from E. 
coli was developed in the lab, which can greatly enhance the expression potential of 
recombinant proteins by the assistance of GroEL chaperone machinery.  This technique has 
been applied to almost all HS and CS biosynthetic enzymes (about 20) and been of greatly 
benefit to many different research projects (45,161,162).  Furthermore, this technique has 
been exported to other laboratories at different research institutions, and has been proved to 
be a widely applicable recombinant protein expression method.  
In comparison to 3OST1 and 3OST3, the solubility of the purified 3OST5 was very 
poor.  In order to make 3OST5 suitable for crystallization trials, we had to first greatly 
enhance its solubility.  Based on the sequence alignment of 3OST enzymes and the structural 
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information from 3OST1 and 3OST3, a highly hydrophobic region in 3OST5 which could 
potentially contribute to its poor solubility was identified.   Mutation of two of the 
hydrophobic residues in 3OST5 to hydrophilic residues dramatically increased the solubility 
of 3OST5 for up to 10 fold (D.Xu and J.Liu, unpublished result).  Only after these solubility 
mutations could 3OST5 be concentrated to a desirable extent for crystallization trials.   
Moreover, we found this hydrophobic region, located within two absolutely conserved 
cysteines that form a disulfide bridge, is unique only to 3OST5.  All other 3OSTs from all 
species have a very hydrophilic sequence in this region, similar to 3OST1 and 3OST3.  
Based one our finding that the solubility of 3OST5 is extremely sensitive to disturbance at 
this region, it is tempting to speculate that this region may play some significant role in the 
biological function of 3OST5.  One possibility is that it may involve in binding to other 
proteins, for example, one of many chaperone proteins, through hydrophobic interactions.  
Indeed, a similar example has been reported in a family of receptor tyrosine kinase (ErbB), 
where only one member (ErbB2) shows association with chaperone Hsp90 through 
hydrophobic interactions (163). 
The crystal structure of 3OST5 was solved at 2.3 Å resolution in a binary complex 
with PAP.  This structure allows us to visualize the differences at the substrate binding site 
among 3OST5, 3OST1 and 3OST3.  Mutational study of 3OST5 is underway to investigate 
the residues in 3OST5 contributing to its substrate promiscuity.  Moreover, further 
modifications on the crystallization method are undergoing to gain faster growing and larger 
crystals of 3OST5.  The optimized crystallization method of 3OST5 would allow the co-
crystalization of 3OST5 with different oligosaccharide sequences, which will ultimately 
reveal the substrate recognition mechanism of 3OSTs.  
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The 2OST crystallization project benefits greatly from the chaperone coexpression 
system, as the N’-His2OST could not be expressed without the assistance of GroEL.  However, 
the N’-His2OST suffers from extremely poor solubility.  We sought to solve this problem by 
first placing the His tag on the C’-temimus of 2OST.  2OSTC’His displayed much higher 
expression levels and afforded a greater than 10 fold increase in solubility.  Furthermore, we 
found that differring truncation lengths at the N-terminus of 2OST had huge effects on the 
solubility.  The difference may be as great as 30 fold as observed between 2OST-1st and 
2OST-5th truncations.  Our experience with 2OST expression suggests that for a certain 
protein, the position of the affinity tag, as well as the size of the N-terminal truncation may 
contribute a great deal to the expression level and the solubility of the recombinant protein.  
Unfortunately, the optimal combination must be determined for each protein experimentally 
in order to achieve the best protein production.   
Despite these efforts, we found that our bacterially expressed 2OST tend to form 
oligomers of different sizes, which may be the major reason preventing good quality crystal 
growth.  This problem could not be easily overcome by applying reducing agents or by 
mutating cysteines involved in disulfide bound formation, two conventional ways to prevent 
oligomerization.  Based on the current system, further modification could be applied in the 
future such as expressing 2OST with a new expression vector that allows periplasmic 
exportation of the recombinant protein for better folding, or expressing 2OSTs from different 
species.  Nevertheless, the current 2OST expression system is robust enough for us to 
conduct a comprehensive mutational study of the enzyme, which will be described in the 
next chapter in details.    
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Chapter V. Mutational Analysis of HS-2OST and CS-2OST  
 
 
In parallel with the crystallization study of HS-2OST, we attempted to use site-directed 
mutagenesis to elucidate the structural features of the enzyme based on its structural 
homology to other members of the sulfotransferase (ST) superfamily.  To enrich the 
structural information obtained from this study, we decided to combine the mutational study 
of chondroitin sulfate 2-O-sulfotransferase (CS-2OST), a CS modification enzyme that is 
56% homologous to HS-2OST in the ST domain, with the mutational study of HS-2OST.  
HS-2OST and CS-2OST catalyze the same reaction at the same sugar residue, but recognize 
different polysaccharide substrates. HS-2OST transfers the sulfo group from PAPS to the 2-
OH position of the hexauronic acid, with a preference for IdoUA, which is adjacent to an 
GlcNS (72); whereas CS-2OST transfers the sulfo group to the 2-OH position of the 
hexauronic acid that is adjacent to an N-acetylated galactosamine residue (GalNAc) carrying 
either a 6-O or 4-O sulfo group (164,165) (Fig. 27).   
Various functions of CS-2OST have been identified by several studies.  The 2-O-
sulfation of IdoUA in a highly sulfated chondroitin sulfate B (dermatan sulfate) 
hexasaccharide sequence contributes to heparin co-factor II binding, regulating the blood 
coagulation cascade (166).  In addition, it has been suggested that a polysaccharide structure 
containing IdoUA(2S)-GalNAc(4S),  IdoUA(2S)-GalNAc(6S) or GlcUA(2S)-GalNAc(6S)  
units exerts potent neurite outgrowth-promoting activities.  These structural motifs contain 2-
O-sulfated glucuronic or 2-O-sulfated iduronic acid residues, which are biosynthesized by 
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CS-2OST,  suggesting an important role of CS-2OST in the development of the mammalian 
central nervous system (167,168).  
 
                                        
 
 
Figure 27.  Structure of the disaccharide repeating units of HS and CS.  The repeating 
disaccharide unit of HS shown is a N-sulfated glucosamine joining to a uronic acid through an 
α→1,4 glycosidic linkage, and the repeating disaccharide unit of CS shown is an N-acetylated 
glucosamine joining to a uronic acid through a β→1,4 glycosidic linkage. The CS- and HS-
2OST modification sites are shaded.  
 
 We have identified six residues in each enzyme that participate in PAPS binding, and 
five residues that potentially mediate substrate binding in HS-2OST and four residues in CS-
2OST. Additionally, we identified two histidine that are essential for the catalytic functions 
of HS-2OST, while one histidine residue was identified in CS-2OST.  The unique structural 
feature in the catalytic sites of HS-2OST and CS-2OST led us identify a homologous protein 
in Drosophila, dmHs2st, as the Drosophila HS-2OST.  Analysis of the previously suggested 
HS-2OST from Drosophila (169), the gene product of pipe, displays neither HS-2OST nor 
CS-2OST activity.  
         
      95
Substrate Specificities of HS-2OST and CS-2OST 
The catalytic domains of HS-2OST and CS-2OST were expressed in E. coli, and the 
substrate specificities of each were determined using five different polysaccharide substrates.  
As shown in table IV, HS-2OST exhibited excellent activity towards CDSNS heparin (94.7 
pmoles/µg of substrate) and moderate activity to N-sulfo heparosan (9.3 pmoles/µg), while it 
showed no activity towards chondroitin sulfate A and C, and only trace amount of activity 
towards chondroitin sulfate B (0.4 pmoles/µg).  CS-2OST showed the best activity to 
chondroitin sulfate A (61.2 pmoles/µg), and to chondroitin sulfate B (31.1 pmoles/µg) and 
moderate activity to chondroitin sulfate C (16.9 pmoles/µg), while it displayed only trace 
amount of activity towards CDSNS heparin and N-sulfo heparosan.  It is important to note 
that the observed CS-2OST substrate profile is largely consistent with the one described in a 
recent report where CS-2OST was expressed in COS-7 cells, observing that the chondroitin 
sulfate A is the best substrate among tested chondroitin/dermatan sulfates (165).  However, 
our results showed that chondroitin sulfate B (dermatan sulfate) can also serve as a substrate 
for CS-2OST, which is consistent with another report on the substrate specificity of CS 
2OST expressed in insect cells (164).  Taken together, our results suggest that bacterially 
expressed recombinant proteins specifically transfer the sulfo group to the hexauronic acid 
that is linked to GlcNS residue (for HS-2OST) and GalNAc residue (for CS-2OST) 
respectively as illustrated in Figure 26. 
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TABLE IV 
Substrate specificities analysis of HS-2OST and CS-2OST 
 
PAPS Binding Residues of HS-2OST and CS-2OST 
The PAPS binding site of HS-2OST—Based on the structures of estrogen 
sulfotransferase (EST) and the HS 3-OSTs, we built a homology model for HS-2OST (Fig. 
28A).  A set of amino acid residues in HS-2OST were identified to be involved in the 
hydrogen-bonding with PAPS.  The residues predicted to contribute to the binding to the 5′-
phosphosulfate group of PAPS include: Lys83, Thr84, Ser86 and Thr87 (Fig. 28B).  Each of 
these residues was then mutated to alanine to test the effects of the mutations on the 
enzymatic activity (Table V).  The mutants exhibited impaired activities, but to differing 
extents.  The K83A and S86A mutations abolished activity, while T87A and T84A show less 
potent but noticeable impairment to the activity.  As expected, the mutant proteins do not 
bind to PAP as determined by ITC (Table V), suggesting that loss or significant impairment 
of sulfotransferase activity is due to the decrease in the binding affinity to PAPS.   
 
 
 
 
 
 
 
 
 
 
 
Substrates Sulfate Transferred by HS-2OST (pmoles/µg) 
Sulfate Transferred by CS-2OST 
(pmoles/µg) 
CDSNS heparin 94.7 1.4 
N-sulfo heparosan 9.3 0.7 
Chondroitin sulfate A < 0.1 61.2 
Chondroitin sulfate B 0.4 31.1 
Chondroitin sulfate C < 0.1 16.9 
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TABLE V 
Analysis of HS-2OST and CS-2OST mutants defective in PAPS binding 
 
Residues involved in binding to the 3′-phosphate group of PAPS were identified to be 
Arg164 and Ser172 (Fig. 28B).  The alanine mutants of these two residues showed significantly 
decreased enzymatic activity, and the binding affinity to PAP is abolished as determined by 
ITC.  These results confirmed that both Arg164 and Ser172 are involved in binding to PAPS.   
PAPS binding site of CS-2OST-Because CS-2OST and HS-2OST have very 
homologous amino acid sequences, the residues involved in binding to the 5′-phosphosulfate 
in CS-2OST are believed to be those corresponding residues in HS-2OST as described above.  
The residues in CS-2OST include Lys112, Cys113, Ser115 and Arg116 (see Fig. 28B for the 
amino acid sequence alignment).  The residues were mutated to alanine and the mutants 
showed diminished sulfotransferase activity in a very similar pattern to that observed for the 
HS-2OST mutants (Table V).  Because the solubility of CS-2OST is low, we could not 
determine the binding affinity (KD) to PAP using ITC.  Instead, we estimated the binding 
affinity of the mutant to PAP using PAP-Agarose affinity chromatography, with a gradient 
concentration of NaCl (77).  All mutants tested were eluted from the PAP-column at lower 
concentration compared to the wild type protein (Table V), suggesting that mutating these 
HS-
2OST      
Mutants 
Activity 
Level 
(%) 
Expression 
Level 
(%) 
PAP 
KD 
(µM) 
 
CS-
2OST    
Mutants 
Activity 
Level 
(%) 
Expression 
Level 
(%) 
PAP column 
elution salt 
concentration 
WT 100 100 18 ± 2  WT 100 100 1100 mM 
         
K83A <1 50 NDa  K112A <1 30 780 mM 
T84A 12± 2 50 ND  C113A 15 ± 5 70 690 mM 
S86A <1 100 ND  S115A <1 85 820 mM 
T87A 6 ± 3 75 ND  R116A 2 ± 1 85 730 mM 
         
R164A 3 ± 2 100 ND  R189A <1 100 630 mM 
S172A 7 ± 1 100 ND  S197A 7 ± 2 110 730 mM 
         
a Not detectable under the condition used, usually has a  KD value greater than  200 µM.  
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residues decreased binding affinity to PAP.  Thus, the results confirmed that those residues 
are involved in binding to PAPS. 
 
                           
 
 
Figure 28.   PAPS binding sites of HS-2OST and CS-2OST.  A. Stereo diagram of the PAPS binding 
sites of HS-2OST and CS-2OST.  Model of the PAPS binding site is generated by using the hEST-
PAP coordinates from 1G3M.  Ser86 of HS-2OST and Arg116 of CS-2OST (shown in transparent 
stick) are modeled in by replacing the Thr50 and Thr51 of hEST respectively. The SO3 group is 
modeled in by overlaying the PAPS from hEST-PAPS (1HY3) to the PAP from 1G3M, shown in 
transparent stick. Putative hydrogen bonds between the side chains and PAP/PAPS are shown in 
dotted lines. The sulfur atom is shown in yellow and phosphor atom is shown in orange.  B. Partial 
sequence alignment of hEST, hHS-2OST, hCS-2OST and hHS-3OST-3 showing sequences roughly 
from the 3'-phosphate PAP binding site to the 5'-phosphate PAP binding site. The secondary 
structures of hEST (top) and hHS-3OST-3 (bottom) are shown in the following scheme: α-helix in 
red tube, β-strand in green arrow, and coil in gray line.  The residues that involve in PAPS binding 
are colored, and the catalytic residues of each enzyme are boxed.  The PAPS binding residues and 
catalytic residues were numbered as in hHS-2OST.  The percentage of amino acid identity with hHS-
2OST and hCS-2OST within the region shown is displayed in the bottom right corner of this figure. 
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Both Arg189 and Ser197 are predicted to bind to the 3′-phosphate of PAPS, based on 
the homology alignment (Fig. 28B).  Indeed, mutants R189A and S197A displayed 
diminished enzymatic activity and reduced binding affinity to PAP (Table V).   
 
Catalytic Residues of HS-2OST and CS-2OST 
It has been suggested that a catalytic base is critical for facilitating deprotonation of 
the acceptor site to allow the sulfuryl-transfer reaction to occur (170).  A structural neighbor 
search of HS-2OST and CS-2OST through GenTHREADER (171) reveals that the enzymes 
are structurally more similar to human EST than to HS 3-OSTs, especially in the β7 region of 
EST (Fig. 28B).  Within this region, the catalytic base of EST, His107, aligns with His142 of 
HS-2OST and His168 of CS-2OST, suggesting that His142 and His168 may serve as a catalytic 
base for HS-2OST and CS-2OST, respectively.  Indeed, His142 is conserved among all HS-
2OST from different species and so is His168 in CS-2OST, suggesting that they are essential 
for enzymatic activities.   
 His142 and His140 in HS-2OST—To address the role of His142 in HS-2OST, a H142A 
mutant was prepared.  This mutant retained around 5% of the wild type HS-2OST activity 
rather than completely abolishing the activity (Table VI), suggesting other residues may also 
be involved in the deprotonation step.  Based on the homology model, His140 may also be 
located near the catalytic site and occupy a position equidistant between the sulfo group of 
PAPS and the acceptor site as His142 (as illustrated in Fig. 29).  Further investigation found 
that the corresponding residue of EST, Lys105, has been suggested to play a role in the 
catalysis of EST (172).  Like His142, His140 in HS-2OST is also conserved across species, 
suggesting that this residue is critical for the sulfotransferase activity.  A H140A mutant was 
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prepared, and exhibited about 4% of the WT HS-2OST activity (Table VI).  To this end, a 
H140A-H142A double mutant was prepared, and indeed, this mutant resulted in a complete 
loss of HS-2OST activity (< 1%) (Table VI).  In order to rule out the possibility that His140 
and His142 bind to PAPS, the mutants H140A, H142A and H140A-H142A were subjected to 
ITC analysis.  The result indicated that all of the mutants retained similar PAP binding 
affinity to that of WT HS-2OST protein (Table VI).  Taken together, the results suggest that 
both histidines are important for the activity of HS-2OST. 
 
Figure 29.  Stereo diagram of the theoretical catalytic site of HS-2OST. The model for the catalytic 
site of HS-2OST is created by superposition of the hEST-PAPS coordinates (1HY3) and the HS-
3OST3 (ternary complex) coordinates (1T8U).  HS sugars 1-3 from the HS 3OST3 coordinates 
(1T8U) are drawn as thin stick in purple. The position of the trisaccharide was adjusted until the 2-OH 
of the iduronic acid lies at the original position of the 3-OH of the glucosamine in the HS 3OST3. The 
6-O-sulfate groups were removed from the GNS-1 (N-sulfoglucosamine 1) and GNS-3 (N-
sulfoglucosamine 3) for ease of viewing. The His140 of HS-2OST was modeled in by replacing the 
Lys105 of hEST with a common rotomer of the histidine sidechain. The sulfate acceptor 2-OH group of 
IDO-2 (iduronic acid) is labeled and shown in magenta. Sulfur groups are shown in yellow. The 
structure diagram is generated by PyMOL.   
 
Role of His168 in CS-2OST —The mutation at His168 in CS-2OST that corresponds to 
His107 in hEST resulted in complete loss of sulfotransferase activity (Table VI).  The binding 
affinity of the H168A mutant to PAPS was estimated by PAP-affinity column.  The mutant 
H168A and wild type CS-2OST eluted at similar salt concentrations suggesting they have 
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similar binding affinities for PAPS.  These results support the hypothesis that His168 is a 
potential catalytic base for the CS-2OST.  Residues Thr166 and Arg167 that are proximate to 
His168 were also tested for the contribution to catalysis because they lie close to His140 of HS-
2OST.  T166A and R167A displayed similar or moderately decreased sulfotransferase 
activity compared to wild type (Table VI), suggesting both residues are nonessential for 
catalysis. 
 
 TABLE VI 
 Analysis of HS-2OST and CS-2OST  mutants defective  in the catalytic function 
 
Substrate Binding Residues of HS-2OST and CS-2OST 
Our efforts for identifying potential substrate binding residues of HS-2OST and CS-
2OST are largely based on their structural homology to the structure of the ternary complex 
of HS 3OST3 with PAP and tetrasaccharide bound (76).  HS 3OST3 interacts with the 
substrate mainly through three regions: around the loop that binds to the 5′-phosphate group 
of PAPS between β2 and α2 (colored in magenta, Fig. 30); at and after α helix 5 (colored in 
yellow, Fig. 30); and the long coil before α helix 11(colored in blue, Fig. 30).  Mutagenesis 
was conducted to examine possible roles for these residues in substrate binding by HS-2OST 
and CS-2OST.  
HS-
2OST      
Mutants 
Activity 
Level 
(%) 
Expression 
Level 
(%) 
PAP 
KD 
(µM) 
 
CS-
2OST 
Mutants 
Activity 
Level 
(%) 
Expression 
Level 
(%) 
PAP column 
elution salt 
Concentration 
WT 100 100  18 ± 2  WT 100 100 1100mM 
         
H140A 4 ± 1 120 33 ± 3   T166A 100 70  N/Aa 
H142A 5 ± 2 150 13 ± 1  R167A 22 ± 2 70 N/A 
H140A/
H142A <1 100 24 ± 2 
 
H168A <1 130 1180mM 
a Not applicable.  
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Roles of Arg80 in HS-2OST and Arg109 in CS-2OST—In the PSB loop region of HS 
3OST3 (between β2 and α2), a lysine residue (Lys161) is involved in binding the carboxyl 
group of the iduronic acid of the tetrasaccharide substrate (colored in magenta, Fig. 30) (76).  
The corresponding residue in HS-2OST is Arg80.  Mutation at Arg80 (R80A) of HS-2OST 
indeed reduced the sulfotransferase activity to about 2.5% of the wild type level (Table VII).  
In addition, the results from ITC analysis demonstrated that R80A binds to PAP with a KD of 
20 µM, very close to the KD of WT HS-2OST at 18 µM (Table VII), suggesting that the 
decreased sulfotransferase activity in R80A is not due to decreased affinity for PAPS.   
In a similar experiment, the R109A mutant of CS-2OST (the corresponding residue 
for Arg80 in HS-2OST) displayed about 4% of the sulfotransferase activity.  Again, this loss 
in activity is not due to reduced PAPS binding as both R109A mutant and wild type proteins 
have similar affinity to PAP as determined by PAP-affinity chromatography (Table VII).   
Roles of Arg178 and Asp181in HS-2OST—In HS-2OST, Arg178and Asp181 are located 
right after the 3′-phosphate PAPS binding region (colored in yellow, Fig. 30), where several 
contacts with the tetrasaccharide substrate have been identified in HS 3OST3 (α helix 5) (76).  
We hypothesize that both Arg178 and Asp181 may interact with the substrate of HS-2OST.  In 
addition, Arg178 and Asp181 are conserved in all vertebrate and invertebrate HS-2OST.  The 
mutants R178A and D181A show significantly decreased sulfotransferase activity although 
the extent of the effect by mutation at Arg178 appears to be greater (Table VII).     
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Figure 30.  The substrate binding regions of HS 3OST3, whose homologous regions were studied in 
HS-2OST and CS-2OST.  A. Three main substrate binding regions of HS 3OST3 are shown in 
cartoon diagram using the coordinates from the HS 3OST3-PAP-tetrasacchride complex (1T8U).  The 
PAPS binding (PSB) loop is shown in magenta (where Arg80 of HS-2OST resides in), the region after 
α helix 5 is shown in yellow (where Arg178, Asp181 and Arg189 of HS-2OST reside in) and the long 
coil region before α helix 11 is shown in blue (where Arg288 of HS-2OST resides in).  The side chains 
of the residues in HS 3OST3 that make direct contact with the tetrasaccharide substrate are shown in 
thin line.  Tetrasaccharide is shown in stick.  The structure diagram is generated by PyMOL.  B. 
Sequence alignments of the HS-2OST and CS-2OST in the above mentioned three regions are shown 
separately in the dashed boxes.  The studied residues are indicated by the residue numbers at the top 
of the alignment for HS-2OST, or at the bottom of the alignment for CS-2OST.  The aligned amino 
acids are boxed and shaded black for identical residues and grey for similar residues, and the 
introduced gaps are shown as dashes. 
 
The binding affinities to PAPS of these mutants were determined by ITC.  The ITC 
analysis showed that D181A binds to PAP with a KD of 27 µM, which is very similar to wild 
type protein, while R178A binds to PAP noticeably weaker with a KD of  100 µM.  Asp181 
could form a hydrogen bond with the OH of the substrate as demonstrated for Asp252 of HS 
3OST3 (76).  The role of Arg178 could be involved in interacting with the substrate,  as well 
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as stabilizing the structure that binds to PAPS.  Indeed, the weaker binding affinity of R178A 
to PAP could be explained by destabilization of helix 5, consequently affecting the 
orientation of Ser172 that binds to the 3′-phosphate of PAPS.      
            The roles of Arg203and Asp206 in CS-2OST— Arg203 and Asp206 in CS-2OST align 
with Arg178 and Asp181 in HS-2OST (Fig. 30B).  Residues Arg203 and Asp206 are conserved in 
CS-2OST from different species.  Mutants R203A and D206A of CS-2OST displayed severe 
defects in sulfotransferase activity (Table VII).  Both R203A and D206A mutants were 
eluted at 900mM and 940 mM NaCl, respectively, from the PAP-affinity column, showing 
that both mutants have somewhat decreased binding affinity for PAP compared to the wild 
type protein (Table VII).  However, mutants defective for PAPS binding were typically 
eluted at the average of 730 mM NaCl from the column, suggesting that the complete loss of 
sulfotransferase activity of R203A and D206A is not solely due to decreased binding affinity 
to PAPS.  
 
TABLE VII 
 Analysis of HS-2OST and CS-2OST mutants potentially defective in substrate binding 
 
HS-
2OST     
Mutants 
Activity 
Level 
(%) 
Expression 
Level 
(%) 
PAP 
KD (µM)  
CS-
2OST    
Mutants 
Activity 
Level 
(%) 
Expression 
Level 
(%) 
PAP column 
elution salt 
Concentration 
WT 100 100 18 ± 2  WT 100 100 1100mM 
         
R80A 2.5 ± 0.5 80 20 ± 1.5  R109A 4 ± 1 170 1170mM 
         
R178A 2 ± 1 80 100 ± 12  R203A <1 20 900mM 
D181A 9 ± 2 60 27 ± 10  D206A <1 130 940mM 
         
R189A 4 ± 0.5 100 13 ± 0.5  R221A 100 100 N/Ab 
         
R288A 7 ± 2 100 8 ± 1  T321A 9 ± 2 90 970mM 
R288T 1.5 ± 0.5 100 NDa  T321R 3 ± 1 80 950mM 
a Not detectable under the condition used, usually has a  KD  value greater than  200 µM. 
b Not applicable. 
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  Role of Arg189 in HS-2OST— Arg189 is located in a region following helix 5 of HS 
3OST3 (colored in yellow, Fig. 30), which is dissimilar between HS-2OST and CS-2OST.  
We speculate that this region may contribute to the substrate specificity differences between 
two enzymes.  In this region, HS-2OST is shorter and contains a stretch of four basic residues, 
RR189RK, whereas CS-2OST is longer and does not contain consecutive basic residues (Fig. 
30B).    Mutating each of these four basic residues in HS-2OST to alanine, we found only the 
mutant R189A significantly reduced the HS-2OST activity (Table VII). All other mutations 
retained greater than 50% of the activity of wild type protein (data not shown).  In addition, 
R189A has comparable binding affinity (13 µM) toward PAP to that of wild type protein (18 
µM), suggesting that the loss of activity of R189A is not due to impaired PAPS binding to 
the enzyme.  Furthermore, we also found that Arg189 is completely conserved ranging from C. 
elegans to humans, implicating the indispensable function of this residue for the enzymatic 
activity of HS-2OST.  Arg221 in CS-2OST is another basic residue in this region.  However, 
the R221A mutant displayed the same activity as the wild type CS-2OST, suggesting that this 
residue is nonessential for the activity of CS-2OST.  Together, our data suggest that Arg189 
interacts with the substrate of HS-2OST.   
Specific Roles of Arg288 of HS-2OST and Thr321 of CS-2OST—Like HS 3OST3, HS-
2OST and CS-2OST have a long coil region that is immediately ahead of the last extended 
helix based on structure prediction (colored in blue, Fig. 30).  In HS 3OST3, this region 
contains several residues, including Thr367, Lys368, Arg370, which interact with the 
nonreducing end saccharide unit of the acceptor.  HS-2OST contains a basic Arg288 that may 
interact with the HS substrate.  The R288A mutant had significantly impaired enzymatic 
activity of HS-2OST, while maintaining a similar binding affinity to PAP similar to that for 
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wild type protein (Table VII).  The corresponding mutation in CS-2OST, T321A, had a 
similar effect on CS-2OST activity albeit with a moderate decrease in PAP binding (Table 
VII), presumably resulting from an indirect influence on PAPS binding.  
Further mutational analysis at Arg288 in HS-2OST and Thr321 in CS-2OST revealed 
the specific requirements of certain residues for the respective sulfotransferase activities.  In 
order to test whether Arg and Thr are interchangeable for HS-2OST and CS-2OST at this 
position, we prepared a R288T mutation in HS-2OST and a T321R mutation in CS-2OST, 
and found that both R288T and T321R lost the activity of their respective enzymes (Table 
VII).  These observations suggest that Arg288 is specifically needed for HS-2OST to interact 
with the HS polysaccharide substrate, while Thr321 is specifically needed for CS-2OST to 
interact with the CS polysaccharide substrate.  We observed differential effects of R288T and 
T321R mutants on PAP-binding.  Mutant R288T resulted in undetectable binding to PAP, 
whereas T321R has a moderate effect on PAP binding (Table VII).  We noted that this area 
interacts with both PAPS and substrate in HS 3OST3.  Thus, disruption of the coil could 
affect PAPS binding affinity.  A similar effect has been observed for Arg370 of HS 3OST3 as 
the nitrogen of the backbone of this residue interacts with the phosphate of PAPS (76). 
 
Characterization of Drosophila HS-2OST 
Drosophila pipe gene expression  in follicle cells has been demonstrated to be 
essential for the establishment of the dorsal-ventral polarity of the future embryo(169,173-
175).  Because pipe encodes a protein family that bears approximately 20-25% identity to the 
ST domain of human HS-2OST, it has been widely speculated that pipe encodes for an 
enzyme that has HS-2OST activity.  However there is no direct evidence suggesting that the 
      107
gene product of pipe has HS-2OST activity.  Interestingly, another Drosophila gene Hs2st 
has also been suggested to encode for the Drosophila HS-2OST (dmHS-2OST), sharing 59% 
identity to the ST domain of human HS-2OST (164).  We decided to determine whether the 
pipe or Hs2st gene products have the activities of HS-2OST and CS-2OST.  
Comparing the distribution of the key amino acid residues for HS-2OST with 
Drosophila proteins suggests that dmHs2st is equivalent to HS-2OST.  From the alignment 
of the three sequences, we observed that pip-PA, pip-PF (two gene products of pipe with 
60% homology) and dmHs2st (gene product of Hs2st) contains the well conserved PAPS 
binding region, and also the four invariable cysteines in the flexible region (Fig. 31).  
However, two major differences suggest that dmHs2st is the best candidate for Drosophila 
HS-2OST.  First, at the catalytic site, dmHs2st contains two histidines that align with His140 
and His142 of HS-2OST, whereas pip-PA/PF has a single histidine near this position.   Second, 
we found dmHs2st contains an aspartic acid at the position of Asp181 in HS-2OST, whereas 
pip-PA/PF has a tryptophan/leucine at the same positions (Fig. 31).  As described above, 
His140, His142, and Asp181 are critical for the activity of HS-2OST.   
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Figure 31.  Multiple amino acid sequence alignment of the human HS-2OST and the Drosophila 
Hs2st, Pip-PA and Pip-PF. The aligned amino acids are boxed and shaded black for identical residues 
and grey for similar residues, and the introduced gaps are shown as dashes. The His142 of hHS-2OST 
is marked by     , while the His140 and Asp181 of hHS-2OST are marked by       .  PAPS binding sites 
are marked by black dots, and the invariant cysteines are marked by grey triangles.  The percentage of 
amino acid identity with dmHs2st and pip-PA within the region shown is displayed in the bottom 
right corner of this figure (BioEdit).  
 
 
To test this experimentally we successfully expressed an N-terminal thioredoxin-
(his)6 tagged fusion protein of dmHs2st (renamed as dmHS-2OST) in E. coli.  The 
sulfotransferase activity and substrate specificity were determined. By comparing the 
susceptibility of dmHS-2OST to various polysaccharide substrates, including CDSNS-
heparin, chondroitin, and chondroitin sulfate A, B, and C,  we found that dmHS-2OST 
displayed essentially the same substrate specificity as hamster HS-2OST, with an enzymatic 
activity exclusively for CDSNS-heparin (60 pmoles/µg).  Furthermore, disaccharide analysis 
of dmHS-2OST-modified CDSNS-heparin demonstrated that it contained the 35S-labeled 
disaccharide with a structure of [2-O-35S]IdoUA2S-AnMan, a characteristic disaccharide 
product resulting from 2OST-modified CDSNS-heparin (Fig. 32).  Thus, dmHS-2OST 
specifically transfers a sulfuryl group to the 2-OH position of IdoUA residue (Fig. 32).  To 
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this end, our results suggest that the gene product of hs2st, dmHs2st, is the Drosophila HS-
2OST.  
Meanwhile, we also successfully expressed two gene products of pipe—pip-PA and 
pip-PF in the form of N-terminal tagged maltose binding protein (MBP) fusion proteins.  The 
resulting MBP-pipPA and MBP-pipPF, even though expressed in large quantities  with good 
solubility, failed to show any HS- or CS-sulfotransferase activities towards the substrates 
tested, including CDSNS heparin, chondroitin, and chondroitin sulfate A, B and C.    
 
                       
Figure 32. RPIP-HPLC chromatograms of the disaccharide analysis of dmHS-2OST modified and 
Chinese hamster HS-2OST modified CDSNS-heparin.  CDSNS-heparin were 2-O-[35S]-labeled by 
dmHS-2OST (or by Chinese hamster HS-2OST) and [35S]PAPS. The labeled heparin was subjected to 
low pH nitrous acid depolymerization, and the resultant [35S]disaccharides were resolved on RPIP-
HPLC.  The elution position of IdoUA2S-AnMan is indicated by arrows, which is identical to the 
disaccharide generated from Chinese hamster (CHO) HS-2OST modified CDSNS-heparin.  
 
 
Conclusion 
Since the molecular cloning of HS-2OST and CS-2OST in the late 90’s, there have 
been numerous studies addressing their substrate specificities, physiological functions, and 
even their interaction with other proteins (27,64,72,74,164,165,176).  Unfortunately, there 
have been no studies addressing structural features and mechanisms of action, which greatly 
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impeded our further understanding of the detailed biochemistry of these two important 
enzymes.  Here, we report the mutational study of HS-2OST and CS-2OST to reveal the 
PAPS binding residues, tpotential catalytic residues and substrate binding residues.  The 
predicted secondary structures and residues with identified functions for HS-2OST and CS-
2OST are summarized in figure 32.  
The PAPS binding sites of HS-2OST and CS-2OST are similar to those of the 
previously characterized sulfotransferases, however, additional structural features are noted.  
We identified four residues that potentially bind to the 5′-phosphate of PAPS, and two 
residues that may bind to the 3′-phosphate of PAPS in both enzymes (labeled as red triangle, 
Fig. 33).  The Thr84 in HS-2OST and Cys113 in CS-2OST align with Ser49 of hEST, however, 
the side chain of Ser49 shows no direct interaction with PAPS in the crystal structure (177).  
Because the mutations of this position resulted in less potent activity impairment, we reason 
that T84A (or C113A) may affect the binding to PAPS indirectly by affecting the 
conformation of the PSB loop.  In addition, we observed that HS-2OST and CS-2OST appear 
to utilize different residues, Thr87 of HS-2OST versus Arg116 of CS-2OST in binding to 
PAPS.  Our homology alignment result suggests that Thr87 and Arg116 align with Thr51 in 
hEST as well as Arg166 in HS 3OST3.  Indeed the backbone amide of Arg166 in HS 3OST3 
and the backbone amide as well as the hydroxyl group of Thr51 in hEST interacts with 5′-
phosphate of PAPS. 
The catalytic sites of HS-2OST and CS-2OST appear similar to that of hEST which 
uses a histidine as a catalytic base rather than the glutamate residue that has been suggested 
for N-deacetylase/N-sulfotransferase and the 3-OSTs (76,77).  For HS-2OST, a double 
mutant H140A/H142A was required to abolish the activity, suggesting both histidine residues 
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are important for catalysis.  In contrast, the single H168A mutation was able to abolish the 
activity of CS-2OST.  His142 in HS-2OST and His168 of CS-2OST align with the catalytic 
base His107 of hEST, which is conserved among all cytosolic STs and many Golgi STs (178), 
whereas His140 is a unique residue only presents among HS-2OST. Without structural data, 
the precise roles of the two histidines in HS-2OST remain unclear.  One possibility is that 
one histidine may function as a base while the other may help stabilize the transition state.  
Alternatively, both residues may be required for binding HS in the proper orientation for 
catalysis.  Another possibility is that His140 and His142 may contribute to the catalysis in a 
complementary manner,  as has been suggested for a few other enzymes (179).  In rat testis 
fructose-2,6-biphosphatase, His256 and His390 have been suggested to perform the catalytic 
function in concert.  Mutations at both His256 and His390 are required to abolish the activity of 
fructose-2,6-biphosphatase (180).  Another example of using two histidine residues in 
catalysis is serum paraoxonase 1, an enzyme catalyzing hydrolysis and formation of various 
lactones.  His115 and His134 of paraoxonase 1 form a histidine dyad in the active site and 
facilitate the catalysis through interactions with one another.  In contrast to fructose-2,6-
biphosphatase, H115Q mutant resulted in a much more potent activity impairment (~1%) 
than did H134Q mutant (~10%) with most substrates used, implicating a primary role of 
His115 and an auxiliary role of His134 in the catalysis of PON1(181,182).  We hope future 
structural studies will shed light on the role of these histidines in catalysis.   
We also explored the potential substrate binding residues in HS-2OST and CS-2OST.  
It appears that the residues involved in binding to the polysaccharide substrate are scattered 
in three regions of the primary sequence (Fig. 30).  Altogether, we identified five residues in 
HS-2OST and four residues in CS-2OST that may potentially mediate substrate binding, 
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excluding the histidine residues involved in catalysis (labeled as yellow squares in Fig. 6).  
Mutations at four aligned residues have resulted in the loss of the activities of HS-2OST and 
CS-2OST, suggesting that the enzymes bind to their respective substrates in a similar fashion.  
The exception among the substrate binding site mutants is D206A of CS-2OST.   Mutant 
D206A of CS-2OST has more potent effect on the enzymatic activity than its counterpart 
mutant in HS-2OST, D181A, implying a more prominent role for Asp206 in the substrate 
binding for CS-2OST.   
A basic residue, Arg189 in HS-2OST, is of special interest.  Mutant R189A has no 
sulfotransferase activity but maintains excellent binding affinity to PAP.  We postulate that 
Arg189 participates in substrate recognition for HS-2OST based on two lines of evidence.  
First, this residue is located in a predicted coil region after helix 5 in HS 3OST3 which is 
very dissimilar between HS-2OST and CS-2OST (Fig. 30).  This region including helix 5 in 
3OST1 and HS 3OST3, contains numerous residues involved in substrate binding.  Second, 
we did not find a similar basic residue in this region in CS-2OST that is essential for the 
sulfotransferase activity.  The positively charged Arg189 in HS-2OST could be involved in 
binding to the negatively charged sulfates of HS polysaccharide substrate.   
In the long coil region (color in blue, Fig. 30), we identified a position that is 
potentially involved in substrate binding, though utilizing different amino acid residues for 
HS-2OST and CS-2OST, respectively.  For example, CS-2OST requires an uncharged 
residue, Thr321, at this position, while HS-2OST requires a positively charged residue, Arg288, 
at this position.  We postulate that Arg288 of HS-2OST and Thr321 of CS-2OST are involved 
in substrate recognition.  It is important to note that Arg370 of HS 3OST3, the corresponding 
residue of Arg288 in HS-2OST, directly interacts with the 2-O-sulfo group of the iduronic 
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acid unit at the nonreducing end of the acceptor site (76).  If Arg288 of HS-2OST plays a 
similar role, this residue could directly interact with the N-sulfo group of the glucosamine 
unit at the nonreducing end of the acceptor site.  In the case of CS-2OST, Thr321 residue 
could form a hydrogen bond with the N-acetyl group of the GalNAc unit.  It is known that 
HS-2OST recognizes the hexauronic acid unit that is adjacent to an N-sulfo glucosamine unit 
carrying a negative charge (72), while CS-2OST recognizes the hexauronic acid unit that is 
adjacent to N-acetylated galactosamine unit (Fig. 27) (176).    
Those residues that are involved in substrate-binding were determined based on the 
homology/dissimilarity to HS 3OST3, of which the substrate-binding sites are known.  We 
note that there is no direct experiment to prove the mutants are defective in substrate binding 
because of the unavailability of the structurally defined substrates.  A heterogeneous 
polysaccharide was used throughout this study.  The complexity of this polysaccharide 
substrate does not allow us to distinguish between the specific substrate/enzyme interactions 
and nonspecific polysaccharide/protein interactions.   
At last, we demonstrated that the distribution of the amino acid residues that are 
essential for HS-2OST and CS-2OST can be used to identify whether a Drosophila protein 
carries 2OST enzymatic activity.  In this experiment, we found that the gene product of Hs2st 
is the Drosophila HS-2OST.  The coexistence of the equivalent residues at His140 and Asp181 
position of HS-2OST helped us recognize unambiguously that the dmHs2st is a HS-2OST, 
which is verified by our in vitro activity assay. To our knowledge, this is the first report 
demonstrating 2OST activity for Drosophila HS-2OST, of which the roles in regulating the 
embryonic development in Drosophila have not yet been explored.   
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Figure 33.  Overview of the predicted structure of HS/CS-2OST and the examined residues.  Aligned 
amino acids are boxed and shaded black for identical residues and grey for similar residues, and the 
introduced gaps are shown as dashes.  The predicted secondary structure (based on predictions by 
GenTHREADER and PredictProtein) is represented on the top of the alignment in the following 
scheme: α-helix in red tube, β-strand in green arrow, coil in gray line, and regions with very low 
prediction confidence in black dot line. The examined residues are marked as following at the bottom 
of the alignment: PAPS binding residues as red triangle, substrate binding residues as yellow square, 
catalytic residues as green circle,  residues with no obvious impairment on activity when mutated as 
x, and the invariant cysteines as star.  
 
 
Our model predicts that two gene products of the Drosophila gene pipe have no HS-
2OST activity.   Indeed, expression of two pipe gene products, pip-PA and pip-PF, was 
achieved.  Both proteins showed neither HS nor CS sulfotransferase activities towards the 
substrates tested.  Our result of pip-PA is consistent with a recent in vivo study using a 
Drosophila strain that is defective in synthesis of the backbone of HS and CS (183), 
suggesting the activity of pip-PA does not depend on either HS or CS.  We noted that 
GlcUA2S or IdoUA2S units, the products of CS-2OST, are not present in CS isolated from 
Drosophila (71,184), suggesting  that pipe proteins are unlikely to carry CS-2OST activity.  
Considering that many CS modification enzymes, such as CS 4-O-sulfotransferases, share 
high homology to STs that sulfate the sugar moiety of glycoproteins (185), it is possible that 
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the pipe genes are responsible for modifying other types of carbohydrate motifs of 
glycoproteins.  Interestingly, HS-2OST is present and highly conserved in all sequenced 
bilarteral animals dated back to flatworm, while CS-2OST can be only identified in 
vertebrates, suggesting that the CS-2OST gene has a unique role in vertebrates.    
In conclusion, we have provided a new body of information on the structural features 
of HS-2OST and CS-2OST through homology and extensive mutagenesis studies. This 
information advances our understanding of the mechanism of action of these enzymes, and 
helps decipher how structural diversity of GAGs is achieved.  
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Chapter VI. Conclusion 
 
As a ubiquitously expressed glycosaminoglyan found at the cell surface and in the 
extracellular matrix, HS plays important roles in multiple physiological and 
pathophyiological processes, and it represents an attractive target for current and future 
pharmaceutical research.   The diverse functions of HS rely on its diverse structures, resulting 
from modifications by many HS biosynthetic enzymes. Unlike proteins and DNA, the 
synthesis of HS is not a template driven process, and thus the genetic control for the 
synthesis of specific saccharide sequences is largely unknown.  A thorough understanding of 
how specific structural patterns of HS are generated and regulated, as well as how specific 
HS structures are involved in distinct biological processes, will eventually lead to a broad 
therapeutic applications of HS or HS-like molecules, or molecules that directly target HS 
biosynthetic enzymes.  Towards this ultimate goal, more research must be performed in 
many disciplines.   
First, the HS modification enzymes, final players dictating the fine structures of HS, 
must be identified and their substrate specificities need to be characterized.  Second, the 
structure-function relationship studies of HS biosynthetic enzymes should be conducted.  
This is especially important, given that HS biosynthesis relies on how these enzymes select 
their appropriate substrates in a controlled manner.  Furthermore, elucidation of the structural 
detail of these enzymes may allow us to synthesize HS-like molecules by designing variants 
of the HS biosynthetic enzymes, possibly assisting the discovery of inhibitors of HS 
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biosynthetic enzymes. Third, how these enzymes are regulated at the transcriptional, 
translational, and posttranslational levels should be elucidated, as these regulation 
mechanisms most likely determine the specific spatial and temporal emergence of unique HS 
structures.  Moreover, this information will eventually connect the biosynthesis of HS to the 
enormous cellular signaling network.  Fourth, the biological functions of the HS biosynthetic 
enzymes should be studied extensively in various model animal systems.  This kind of study 
will not only validate the reliability of the knowledge we gained from biochemical or 
structural studies, but also serve as an indispensable bridge to connect the basic scientific 
study of HS to the therapeutic applications of HS.  
One of the major focuses of the HS field in the past ten years has been the 
identification and characterization of HS biosynthetic enzymes.  As a collective effort of 
many labs, all HS biosynthetic enzymes have been cloned and characterized.  My first work, 
molecular cloning and characterization of 3OST6, contribute to this significant effort (12).  
We have cloned this enzyme for the first time and analyzed its substrate specificity.  
Moreover, by using a CHO cell line that stably expresses 3OST6, we determined that 3OST6 
modified HS at the cell surface could be utilized by HSV-1 as an entry receptor for infection, 
and could also assist the spreading of the viruses via induction of cell-cell fusion.  This work 
provided the basic biochemical information about the last member of the 3OST enzyme 
family, and will expectedly serve as the basis for future studies regarding the biological 
functions of 3OST6.  
The greatest mystery of HS biosynthesis is how specific structural motifs are 
generated and regulated.  Fully appreciating this intriguing phenomenon is by no means an 
easy task, but a good starting point would be to understand how HS modification enzymes 
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recognize their respective substrates.  It is, after all, the modifications enzymes that execute 
the chemical reactions.  It is widely conceived that the atomic structure of a protein will 
provide some of the most important information about its mechanism of action.  However, 
the structural information of HS modification enzymes has been scarce and represents a 
substantial gap in our knowledge that must be filled.   Our lab has been involved in the 
structure-function relationship study of HS modification enzymes in the past few years, in 
collaboration with Dr. Pedersen’s X-ray crystallography group at the National Institute of 
Environmental Health Sciences.  Our collaboration has successfully solved the crystal 
structures of 3OST1 and 3OST3 (76,77).  Much important information has been revealed 
regarding the mechanism of action of the 3OST enzyme family, but structural studies on 
more family members is necessary to understand the detailed substrate recognition 
mechanism.   
My second project attempted to solve the crystal structures of 3OST5 in complex 
with two different HS substrates.  This work will provide a great structural model to study 
the substrate recognition mechanism because the promiscuity of 3OST5 allows it to interact 
with many different HS structures.  An efficient recombinant protein expression system using 
E.coli was developed.  This system not only made the crystallization studies of 3OST5 
possible, but also aided the recombinant expression of many other HS and CS biosynthetic 
enzymes in the lab (45,161,162).  Moreover, a unique hydrophobic surface region of 3OST5 
was identified, which was shown to contribute to the poor solubility of 3OST5.   Mutations at 
this region significantly increased the solubility of 3OST5 and allowed us to grow crystals of 
the enzyme (D.Xu and J.Liu, unpublished result).  A more intriguing question raised by this 
finding is that of the biological function of this exposed hydrophobic region.   We speculate 
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this region may involve in the intermolecular interaction of 3OST5 with other proteins, 
which may have some regulatory function on the activity or availability of the enzymes.  
Further studies focus on this region may reveal novel a posttranslational regulatory 
mechanism for 3OST5.  
Using the I299E mutant, we were able to solve the crystal structure of 3OST5 at 2.3-
Å resolution in a binary complex with with PAP.  Based on the structure, multiple mutations 
of 3OST5 were designed to investigate the residues contributing to the broad substrate 
specificity of 3OST5.    Moreover, further modifications on the crystallization method are 
underway to gain faster growing and larger crystals of 3OST5, which will facilitate co-
crystallization of 3OST5 with different oligosaccharide substrates.  
My last project has been the structural study of HS-2OST.  In parallel with the 
crystallization study, we tried to outline the structure of HS-2OST by undertaking a 
mutational study.  Moreover, the mutational study of HS-2OST was combined with the 
mutational study of CS-2OST, a CS modification enzyme that very homologous to HS-2OST 
yet recognizes quite different substrates.    Mutational approach played a unique role in the 
structure-function relationship study in that, first, it is an essential accompanying method for 
verification of the conclusions we draw from the pure structural studies; and second, it allows 
us to pinpoint the residues critical for the protein activity even when the detailed structural 
information is not available.   In the mutational study of HS-2OST and CS-2OST, we sought 
to identify the residues that are essential for the action of the two enzymes based on the 
structural homologue between themselves as well as other sulfotransferases of known 
structure.  We characterized a set of essential residues for both enzymes including PAPS 
binding residues, substrate binding residues and catalytic residues.  HS-2OST and CS-2OST 
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showed common as well as dissimilar arrangements of substrate binding residues, providing 
clues about how they distinguish HS versus CS chains.  Unexpectedly, we discovered that 
HS-2OST is likely to have a special catalytic site that is not seen in other sulfotransferases, 
which might have significant correlation with the substrate selection mechanism of the 
enzyme.  Furthermore, this conserved catalytic site of HS-2OST prompted us to 
experimentally clarify the identity of the authentic HS-2OST in Drosophila (78).  
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